L44 1 SEA FILE=EMBASE ABB=ON L41 AND L42 AND L43

FILE 'DRUGU' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'JICST-EPLUS' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 16:17:54 ON 21 MAR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:17:54 ON 21 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'WPIDS' ENTERED AT 16:17:54 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

L1 23 SEA FILE=HCAPLUS ABB=ON RIZZIERI D?/AU
L2 272 SEA FILE=HCAPLUS ABB=ON BIGNER D?/AU
L3 200 SEA FILE=HCAPLUS ABB=ON ZALUTSKY M?/AU
L63 186 SEA L1
L64 1323 SEA L2
L65 647 SEA L3
L83 9 SEA L63 AND L64 AND L65

=> dup rem l28,l4,l44,l83
FILE 'MEDLINE' ENTERED AT 16:18:03 ON 21 MAR 2005

FILE 'HCAPLUS' ENTERED AT 16:18:03 ON 21 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:18:03 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'PASCAL' ENTERED AT 16:18:03 ON 21 MAR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:18:03 ON 21 MAR 2005

=> fil hcapl; d que l4; fil medl cancer; d que l28; fil embase; d que l44; fil DRUGU, JICST-EPLUS, PASCAL, BIOTECHNO, ESBIOBASE, BIOSIS, BIOTECHDS, DISSABS, WPIDS; d que l83
FILE 'HCAPLUS' ENTERED AT 16:17:53 ON 21 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Mar 2005 VOL 142 ISS 13
FILE LAST UPDATED: 20 Mar 2005 (20050320/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

Inventor search

L1 23 SEA FILE=HCAPLUS ABB=ON RIZZIERI D?/AU
L2 272 SEA FILE=HCAPLUS ABB=ON BIGNER D?/AU
L3 200 SEA FILE=HCAPLUS ABB=ON ZALUTSKY M?/AU
L4 2 SEA FILE=HCAPLUS ABB=ON L1 AND L2 AND L3

FILE 'MEDLINE' ENTERED AT 16:17:53 ON 21 MAR 2005

FILE 'CANCERLIT' ENTERED AT 16:17:53 ON 21 MAR 2005

L1 23 SEA FILE=HCAPLUS ABB=ON RIZZIERI D?/AU
L2 272 SEA FILE=HCAPLUS ABB=ON BIGNER D?/AU
L3 200 SEA FILE=HCAPLUS ABB=ON ZALUTSKY M?/AU
L25 63 SEA L1
L26 832 SEA L2
L27 323 SEA L3
L28 1 SEA L25 AND L26 AND L27

FILE 'EMBASE' ENTERED AT 16:17:53 ON 21 MAR 2005

FILE COVERS 1974 TO 17 Mar 2005 (20050317/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L41 40 SEA FILE=EMBASE ABB=ON RIZZIERI D?/AU
L42 367 SEA FILE=EMBASE ABB=ON BIGNER D?/AU
L43 179 SEA FILE=EMBASE ABB=ON ZALUTSKY M?/AU

FILE 'BIOSIS' ENTERED AT 16:18:03 ON 21 MAR 2005

FILE 'BIOTECHDS' ENTERED AT 16:18:03 ON 21 MAR 2005

FILE 'WPIDS' ENTERED AT 16:18:03 ON 21 MAR 2005

PROCESSING COMPLETED FOR L28
PROCESSING COMPLETED FOR L4
PROCESSING COMPLETED FOR L44
PROCESSING COMPLETED FOR L83
L88 5 DUP REM L28 L4 L44 L83 (8 DUPLICATES REMOVED)
ANSWER '1' FROM FILE MEDLINE
ANSWER '2' FROM FILE HCAPLUS
ANSWERS '3-5' FROM FILE BIOSIS

=> d iall 1; d ibib ed abs hitind 2; d iall 3-5

L88 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2004362017 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15100153
TITLE: Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
AUTHOR: **Rizzieri David A**; Akabani Gamal; **Zalutsky Michael R**; Coleman R Edward; Metzler Scott D; Bowsher James E; Toaso Bonnie; Anderson Elizabeth; Lagoo Anand; Clayton Steve; Pegram Charles N; Moore Joseph O; Gockerman Jon P; DeCastro Carlos; Gasparetto Cristina; Chao Nelson J; **Bigner Darell D**
CORPORATE SOURCE: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.. rizzi003@mc.duke.edu
CONTRACT NUMBER: CA11898 (NCI)
CA70164 (NCI)
S10RR15697.7 (NCRR)
SOURCE: Blood, (2004 Aug 1) 104 (3) 642-8. Electronic Publication: 2004-04-20.
Journal code: 7603509. ISSN: 0006-4971.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200408
ENTRY DATE: Entered STN: 20040722
Last Updated on STN: 20040831
Entered Medline: 20040830

ABSTRACT:
We report a phase 1 study of pharmacokinetics, dosimetry, toxicity, and response of (131)I anti-tenascin chimeric 81C6 for the treatment of lymphoma. Nine patients received a dosimetric dose of 370 MBq (10 mCi). Three patients received an administered activity of 1480 MBq (40 mCi), and 2 developed hematologic toxicity that required stem cell infusion. Six patients received an administered activity of 1110 MBq (30 mCi), and 2 developed toxicity that required stem cell infusion. The clearance of whole-body activity was monoexponential with a mean effective half-life of 110 hours (range, 90-136 hours) and a mean effective whole-body residence time of 159 hours (range, 130-196 hours). There was rapid uptake within the viscera; however, tumor

uptake was slower. Activity in normal viscera decreased proportional to the whole body; however, tumor sites presented a slow clearance (T(1/2), 86-191 hours). The mean absorbed dose to whole-body was 67 cGy (range, 51-89 hours), whereas the dose to tumor sites was 963 cGy (range, 363-1517 cGy). Despite lack of a "blocking" antibody, 1 of 9 patients attained a complete remission and 1 a partial remission. These data demonstrate this radiopharmaceutical to be an encouraging agent for the treatment of lymphoma particularly if methods to protect the normal viscera are developed.

CONTROLLED TERM: Check Tags: Female; Male
Animals
Antibodies, Monoclonal: PK, pharmacokinetics
*Antibodies, Monoclonal: TO, toxicity
Biological Transport
Biopsy
Bone Marrow: PA, pathology
Humans
Immunotoxins: PK, pharmacokinetics
Immunotoxins: TO, toxicity
Iodine Radioisotopes: PK, pharmacokinetics
*Iodine Radioisotopes: TO, toxicity
Lymph Nodes: PA, pathology
Lymphoma, Non-Hodgkin: PA, pathology
*Lymphoma, Non-Hodgkin: RT, radiotherapy
Mice
Patient Selection
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Tenascin: AN, analysis
Tissue Distribution
Tomography, X-Ray Computed

CHEMICAL NAME: 0 (Antibodies, Monoclonal); 0 (Immunotoxins); 0 (Iodine Radioisotopes); 0 (Tenascin)

L88 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2002:504652 HCAPLUS
DOCUMENT NUMBER: 137:59618
TITLE: Anti-tenascin monoclonal antibody therapy for lymphoma
INVENTOR(S): **Rizzieri, David; Bigner, Darell D.** ; **Zalutsky, Michael**
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051448	A1	20020704	WO 2001-US46104	20011024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002187100 A1 20021212 US 2001-8062 20011019
EP 1351713 A1 20031015 EP 2001-996085 20011024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2000-257108P P 20001221
WO 2001-US46104 W 20011024

ED Entered STN: 05 Jul 2002
AB A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as 131I.
IC ICM A61K051-10
ICS A61K039-395; C07K016-28; C07K016-30
CC 8-7 (Radiation Biochemistry)
Section cross-reference(s): 1, 15
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2004:152011 BIOSIS
DOCUMENT NUMBER: PREV200400147666
TITLE: Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using 131I labeled chimeric anti-tenascin therapy for lymphoma.
AUTHOR(S): **Rizzieri, David A.** [Reprint Author]; Akabani, Gamal; **Zalutsky, Michael**; Coleman, R. Edward; Toaso, Bonnie [Reprint Author]; Anderson, Elizabeth [Reprint Author]; Lagoo, Anand; Clayton, Steve; Niedzwiecki, Donna; Moore, Joseph O. [Reprint Author]; Gockerman, Jon P. [Reprint Author]; DeCastro, Carlos [Reprint Author]; Chao, Nelson J. [Reprint Author]; Gasparetto, Cristina [Reprint Author]; **Bigner, Darell D.**
CORPORATE SOURCE: Dept. of Medicine, Duke University Medical Center, Durham, NC, USA
SOURCE: Blood, (November 16 2003) Vol. 102, No. 11, pp. 635a-636a. print.
Meeting Info.: 45th Annual Meeting of the American Society of Hematology. San Diego, CA, USA. December 06-09, 2003. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Mar 2004
Last Updated on STN: 17 Mar 2004
ABSTRACT:Background: We and others have shown the importance of stromal changes such as microvasculature and extracellualr matrix protein expression in the progression of lymphoma. Tenascin is one of the stromal proteins that is overexpressed in lymphomatous tissue compared to normal visceral sites. Further, unlike other targets for available radiolabeled antibodies, tenascin expression is increased with aggressiveness and grade of disease(Rizzieri et al., Blood (Suppl 1) 94:4339, 1999). We present the results of a phase I study of stromally directed therapy using a human-mouse chimeric antibody to tenascin that is labeled with 131I and given intravenously to patients with lymphoma. Methods: Patients are given an initial dose (10mCi 131I on 10mg of antibody) to

obtain dosimetry and pharmacokinetic data during the subsequent week. The therapeutic dose (30-40mCi on 10mg of tenascin antibody) is delivered 1-2 weeks later and patients followed for toxicity and response. This first phase I trial does not include a 'cold' antibody to block nonspecific binding. Results: Toxicity was limited to dose limiting neutropenia or thrombocytopenia with a maximum dose of 30mCi for the therapy dose. Dosimetry revealed a 4-5:1 ratio of tumor to normal tissue concentration of radiolabel, despite this first phase I study not having a 'blocking antibody' for non-specific binding. Pharmacokinetic studies revealed prolonged exposure to the radiolabeled antibody with a range of 100-169 hours. One can note rapid uptake in the marrow and liver, with a slower, yet more pronounced uptake in the tumor bed. The radiolabeled antibody has a prolonged halflife, mirroring the breakdown of the radiolablel, indicating that it is not re-circulated and excreted. Conclusion: Anti-stromal therapy using a chimeric, monoclonal radiolabeled antibody to tenascin is an encouraging method of targeting lymphoma. Future trials will focus on decreasing nonspecific binding and escalating the dose absorbed by the tumor.

CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Pathology - Diagnostic 12504
Pathology - Therapy 12512
Digestive system - Physiology and biochemistry 14004
Blood - Blood and lymph studies 15002
Blood - Blood cell studies 15004
Blood - Blood, lymphatic and reticuloendothelial pathologies 15006
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Toxicology - General and methods 22501
Toxicology - Pharmacology 22504
Neoplasms - Diagnostic methods 24001
Neoplasms - Immunology 24003
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Blood and reticuloendothelial neoplasms 24010
Immunology - General and methods 34502
Immunology - Immunopathology, tissue immunology 34508

INDEX TERMS: Major Concepts
Clinical Immunology (Human Medicine, Medical Sciences); Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pharmacology

INDEX TERMS: Parts, Structures, & Systems of Organisms
bone marrow: blood and lymphatics, immune system; liver: digestive system

INDEX TERMS: Diseases
lymphoma: blood and lymphatic disease, immune system disease, neoplastic disease, diagnosis, drug therapy
Lymphoma (MeSH)

INDEX TERMS: Diseases
neutropenia: blood and lymphatic disease, toxicity, drug-induced
Neutropenia (MeSH)

INDEX TERMS: Diseases
thrombocytopenia: blood and lymphatic disease, toxicity, drug-induced
Thrombocytopenia (MeSH)

INDEX TERMS: Diseases
toxicity: toxicity

INDEX TERMS: Chemicals & Biochemicals
iodine 131; tenascin: toxicity

INDEX TERMS: Methods & Equipment
Iodine 131 labeled chimeric anti-tenascin therapy:

clinical techniques, therapeutic and prophylactic techniques; anti-stromal therapy: clinical techniques, therapeutic and prophylactic techniques; dosimetry: laboratory techniques

INDEX TERMS: Miscellaneous Descriptors
pharmacokinetics, dosimetry, toxicity and response of anti-stromal therapy; phase I trial

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common): patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 10043-66-0 (iodine 131)

L88 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2002:474119 BIOSIS
DOCUMENT NUMBER: PREV200200474119
TITLE: Radioimmunotherapy of refractory non-Hodgkin's lymphoma with 131I-labeled chimeric 81C6 anti-tenascin monoclonal antibody: Dosimetry study.
AUTHOR(S): Akabani, G. [Reprint author]; **Rizzieri, D.** [Reprint author]; Coleman, R. E. [Reprint author]; Metzler, S. D. [Reprint author]; **Zalutsky, M. R.** [Reprint author]; **Bigner, D. D.** [Reprint author]
CORPORATE SOURCE: Duke University Medical Center, Durham, NC, USA
SOURCE: Journal of Nuclear Medicine, (May, 2002) Vol. 43, No. 5 Supplement, pp. 313P. print.
Meeting Info.: 49th Annual Meeting of the Society of Nuclear Medicine. Los Angeles, CA, USA. June 15-19, 2002.
CODEN: JNMEAQ. ISSN: 0161-5505.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 11 Sep 2002
Last Updated on STN: 11 Sep 2002
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Radiation biology - Radiation and isotope techniques 06504
Biochemistry studies - Proteins, peptides and amino acids 10064
Pathology - Therapy 12512
Blood - Blood, lymphatic and reticuloendothelial pathologies 15006
Pharmacology - General 22002
Pharmacology - Drug metabolism and metabolic stimulators 22003
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
Neoplasms - Blood and reticuloendothelial neoplasms 24010
Immunology - Immunopathology, tissue immunology 34508
INDEX TERMS: Major Concepts
Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pharmacology; Radiology (Medical Sciences)

INDEX TERMS: Diseases
non-Hodgkin's lymphoma: blood and lymphatic disease, immune system disease, neoplastic disease
Lymphoma, Non-Hodgkin (MeSH)
INDEX TERMS: Chemicals & Biochemicals
81C6 anti-tenascin monoclonal antibody: dosimetry, iodine-131 labeled, pharmacokinetics; tenascin: glycoprotein
INDEX TERMS: Methods & Equipment
radioimmunotherapy: immunologic method, radiologic method, therapeutic method
INDEX TERMS: Miscellaneous Descriptors
Meeting Abstract; Meeting Poster
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

L88 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2002:152427 BIOSIS
DOCUMENT NUMBER: PREV200200152427
TITLE: Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL).
AUTHOR(S): **Rizzieri, David A.** [Reprint author]; Akabani, Gamal; Coleman, R. Edward; **Zalutsky, Michael R.**; Niedzwiecki, Donna [Reprint author]; Payne, Nancy [Reprint author]; Wikstrand, Carol; **Bigner, Darell D.**
CORPORATE SOURCE: Division of Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC, USA
SOURCE: Blood, (November 16, 2001) Vol. 98, No. 11 Part 2, pp. 247b. print.
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 2. Orlando, Florida, USA. December 07-11, 2001. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 21 Feb 2002
Last Updated on STN: 26 Feb 2002

ABSTRACT:Tenascin (TN), an extracellular matrix glycoprotein that is significantly over-expressed in multiple tumor types, including breast cancer, lung cancer, GI tumors, brain tumors, and lymphomas. Interestingly, TN over-expression in tumorous tissue increases with more aggressive grades of lymphoma. Further, within the same patient, over-expression is limited to the tumor site. These data suggest the stroma of the tumor may be an attractive target for therapy. We have created a humanized murine antibody to tenascin and radiolabeled it with I-131. Patients with relapsed or refractory NHL who are not candidates for high dose therapy, have not been previously radiated to tissue tolerance, do not have >25% marrow involvement with disease, have normal blood counts and adequate liver/renal function were eligible. We have treated 2 patients to date. The first had refractory well differentiated lymphoma following 3 different chemotherapy and rituximab regimens without any significant response. The second patient had diffuse large cell lymphoma refractory to 3 standard regimens of chemotherapy. For dosimetry, 10 mg of antibody was labeled with 10 mCi of I-131 and infused as a bolus. Following a week of daily gamma camera imaging and pharmacokinetic analyses, pts were

treated with a therapeutic dose of 40 mCi I-131 conjugated to 10 mg of anti-tenascin antibody. No cold blocking antibody was given prior to labeled dose in this phase I trial. The whole-body, visceral organ, and tumor dosimetry are given. The whole-body effective half life and residence time in patient 1 was 116 hours and 167 hours respectively and for patient 2 was 109 hours and 158 hours, respectively. Even without a cold dose for blocking of non-specific uptake, the tumor still concentrates the radiolabeled antibody at a ratio of 5X over visceral organs. Each patient noted 1 night sweat and mild diarrhea the night of therapy, and low grade fever persisting for a few days. Both patients experienced transient myelosuppression occurring between weeks 4-6 from therapy. With early follow up of 1-3 months, both have responded with decreased tumor size, though the maximum response is not yet determined. The above dosimetry estimates and prolonged residency time are very encouraging. The increased TN expression in more aggressive lymphomas and many other tumors such as breast cancer, lung cancer, and gastrointestinal malignancies suggests this targeted radiotherapy may have broad applicability. These results, as well as the clinical outcomes for the patients, support further evaluation of anti-stromal targeted therapy with radiolabeled, anti-tenascin antibody.

CONCEPT CODE:
General biology - Symposia, transactions and proceedings 00520
Radiation biology - Radiation and isotope techniques 06504
Pathology - Therapy 12512
Digestive system - Physiology and biochemistry 14004
Digestive system - Pathology 14006
Blood - Blood and lymph studies 15002
Blood - Blood cell studies 15004
Blood - Blood, lymphatic and reticuloendothelial pathologies 15006
Respiratory system - Physiology and biochemistry 16004
Respiratory system - Pathology 16006
Reproductive system - Physiology and biochemistry 16504
Reproductive system - Pathology 16506
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Immunology 24003
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
Neoplasms - Blood and reticuloendothelial neoplasms 24010
Immunology - General and methods 34502
Immunology - Immunopathology, tissue immunology 34508

INDEX TERMS: Major Concepts
Clinical Immunology (Human Medicine, Medical Sciences); Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pharmacology; Radiology (Medical Sciences)

INDEX TERMS: Parts, Structures, & Systems of Organisms
blood: blood and lymphatics, digestive system; bone marrow: blood and lymphatics, immune system; breast: reproductive system; liver: digestive system; lung: respiratory system

INDEX TERMS: Diseases
breast cancer: neoplastic disease, reproductive system disease/female
Breast Neoplasms (MeSH)

INDEX TERMS: Diseases
diffuse large cell lymphoma: blood and lymphatic disease, immune system disease, neoplastic disease, therapy
Lymphoma, Large-Cell, Diffuse (MeSH)

INDEX TERMS: Diseases

gastrointestinal malignancy: digestive system disease, neoplastic disease

INDEX TERMS: Diseases
lung cancer: neoplastic disease, respiratory system disease
Lung Neoplasms (MeSH)

INDEX TERMS: Diseases
refractory non-Hodgkin's lymphoma: blood and lymphatic disease, immune system disease, neoplastic disease, therapy, refractory NHL
Lymphoma, Non-Hodgkin (MeSH)

INDEX TERMS: Chemicals & Biochemicals
cold blocking antibody; iodine-131; radiolabeled anti-tenascin antibody: antineoplastic-drug; rituximab: antineoplastic-drug; tenascin [TN]: expression

INDEX TERMS: Methods & Equipment
chemotherapy: therapeutic method; dosimetry: analytical method; pharmacokinetic analysis: analytical method; targeted radiotherapy: therapeutic method

INDEX TERMS: Miscellaneous Descriptors
adequate liver function; adequate renal function; tissue tolerance radiation; transient myelosuppression; Meeting Abstract

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 10043-66-0 (iodine-131)
174722-31-7 (rituximab)

```
=> => fil hcapl; d que l13; d que l14; d que l16
FILE 'HCAPLUS' ENTERED AT 16:21:03 ON 21 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Mar 2005  VOL 142 ISS 13
FILE LAST UPDATED: 20 Mar 2005  (20050320/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


L5          19252 SEA FILE=HCAPLUS ABB=ON  LYMPHOMA+OLD,NT/CT
L10          1386 SEA FILE=HCAPLUS ABB=ON  IMMUNORADIOTHERAPY+OLD/CT
L12          1707 SEA FILE=HCAPLUS ABB=ON  (TENASCIN# OR BRACHONECTIN# OR
                  CYTOTACTIN# OR HEXABRACHION#)/OBI
L13             6 SEA FILE=HCAPLUS ABB=ON  L5 AND L10 AND L12


L5          19252 SEA FILE=HCAPLUS ABB=ON  LYMPHOMA+OLD,NT/CT
L6         222803 SEA FILE=HCAPLUS ABB=ON  ANTIBOD?/OBI
L7         102765 SEA FILE=HCAPLUS ABB=ON  LABEL?/OBI
L8           6646 SEA FILE=HCAPLUS ABB=ON  RADIOLABEL?/OBI
L9          12055 SEA FILE=HCAPLUS ABB=ON  RADIOISOTOP?/OBI
L11         18113 SEA FILE=HCAPLUS ABB=ON  RADIOTHERAP?/OBI
L12          1707 SEA FILE=HCAPLUS ABB=ON  (TENASCIN# OR BRACHONECTIN# OR
                  CYTOTACTIN# OR HEXABRACHION#)/OBI
L14            13 SEA FILE=HCAPLUS ABB=ON  L5 AND L6 AND L12 AND ((L7 OR L8 OR
                  L9) OR L11)


L5          19252 SEA FILE=HCAPLUS ABB=ON  LYMPHOMA+OLD,NT/CT
L7         102765 SEA FILE=HCAPLUS ABB=ON  LABEL?/OBI
L8           6646 SEA FILE=HCAPLUS ABB=ON  RADIOLABEL?/OBI
L9          12055 SEA FILE=HCAPLUS ABB=ON  RADIOISOTOP?/OBI
L11         18113 SEA FILE=HCAPLUS ABB=ON  RADIOTHERAP?/OBI
L12          1707 SEA FILE=HCAPLUS ABB=ON  (TENASCIN# OR BRACHONECTIN# OR
                  CYTOTACTIN# OR HEXABRACHION#)/OBI
L15            20 SEA FILE=HCAPLUS ABB=ON  81C6/OBI
L16             2 SEA FILE=HCAPLUS ABB=ON  L5 AND L15 AND L12 AND ((L7 OR L8 OR
                  L9) OR L11)

=> s (l13 or l14 or l16) not l4
L89            13 (L13 OR L14 OR L16) NOT L4
```

previously printed w/ inventor search

```
=> fil medl cancer; d que l33; d que l40

FILE 'MEDLINE' ENTERED AT 16:21:05 ON 21 MAR 2005

FILE 'CANCERLIT' ENTERED AT 16:21:05 ON 21 MAR 2005


L29         2096 SEA TENASCIN/CT
L30       221519 SEA LYMPHOMA+NT/CT
L31       221894 SEA RADIOISOTOPES+NT/CT
L32       626312 SEA ANTIBODIES+NT/CT
L33            1 SEA L29 AND L30 AND L31 AND L32


L29         2096 SEA TENASCIN/CT
L30       221519 SEA LYMPHOMA+NT/CT
L39         2605 SEA RADIOIMMUNOTHERAPY/CT
L40            0 SEA L29 AND L30 AND L39

=> s l33 not l28

L90            0 L33 NOT L28  previously printed

=> fil embase; d que l58; d que l59; d que l60; d que l62

FILE 'EMBASE' ENTERED AT 16:21:07 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

 FILE COVERS 1974 TO 17 Mar 2005 (20050317/ED)

 EMBASE has been reloaded. Enter HELP RLOAD for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


L45            3 SEA FILE=EMBASE ABB=ON  TENASCIN MONOCLONAL ANTIBODY/CT OR
                 TENASCIN MONOCLONAL ANTIBODY 81C6/CT OR TENASCIN MONOCLONAL
                 ANTIBODY 81C6 I 131/CT
L57        82084 SEA FILE=EMBASE ABB=ON  LYMPHOMA+NT/CT
L58            1 SEA FILE=EMBASE ABB=ON  L57 AND L45


L46         1888 SEA FILE=EMBASE ABB=ON  TENASCIN/CT
L47         4387 SEA FILE=EMBASE ABB=ON  RADIOPHARMACEUTICAL AGENT/CT
L48          208 SEA FILE=EMBASE ABB=ON  RADIATION CHIMERA/CT
L50        17865 SEA FILE=EMBASE ABB=ON  CANCER IMMUNOTHERAPY/CT
L51        42647 SEA FILE=EMBASE ABB=ON  CANCER RADIOTHERAPY/CT
L52            3 SEA FILE=EMBASE ABB=ON  RADIOIMMUNOTHERAPEUTIC AGENT/CT
L53         1841 SEA FILE=EMBASE ABB=ON  RADIOIMMUNOTHERAPY/CT
L55         2361 SEA FILE=EMBASE ABB=ON  RADIOISOTOPE THERAPY/CT
L56       410315 SEA FILE=EMBASE ABB=ON  RADIOISOTOPE+NT/CT
L57        82084 SEA FILE=EMBASE ABB=ON  LYMPHOMA+NT/CT
L59            2 SEA FILE=EMBASE ABB=ON  L46 AND L57 AND L50 AND ((L47 OR L48)
                 OR (L51 OR L52 OR L53) OR L55 OR L56)
```

```
L46          1888 SEA FILE=EMBASE ABB=ON  TENASCIN/CT
L48           208 SEA FILE=EMBASE ABB=ON  RADIATION CHIMERA/CT
L53          1841 SEA FILE=EMBASE ABB=ON  RADIOIMMUNOTHERAPY/CT
L57         82084 SEA FILE=EMBASE ABB=ON  LYMPHOMA+NT/CT
L60             2 SEA FILE=EMBASE ABB=ON  L46 AND L57 AND (L53 OR L48)


L46          1888 SEA FILE=EMBASE ABB=ON  TENASCIN/CT
L47          4387 SEA FILE=EMBASE ABB=ON  RADIOPHARMACEUTICAL AGENT/CT
L48           208 SEA FILE=EMBASE ABB=ON  RADIATION CHIMERA/CT
L49         26198 SEA FILE=EMBASE ABB=ON  ISOTOPE LABELING/CT
L50         17865 SEA FILE=EMBASE ABB=ON  CANCER IMMUNOTHERAPY/CT
L51         42647 SEA FILE=EMBASE ABB=ON  CANCER RADIOTHERAPY/CT
L52             3 SEA FILE=EMBASE ABB=ON  RADIOIMMUNOTHERAPEUTIC AGENT/CT
L53          1841 SEA FILE=EMBASE ABB=ON  RADIOIMMUNOTHERAPY/CT
L54        310383 SEA FILE=EMBASE ABB=ON  ANTIBODY+NT/CT
L55          2361 SEA FILE=EMBASE ABB=ON  RADIOISOTOPE THERAPY/CT
L56        410315 SEA FILE=EMBASE ABB=ON  RADIOISOTOPE+NT/CT
L57         82084 SEA FILE=EMBASE ABB=ON  LYMPHOMA+NT/CT
L62             4 SEA FILE=EMBASE ABB=ON  (L50 OR L54) AND L46 AND L57 AND ((L47
                  OR L48 OR L49) OR (L51 OR L52 OR L53) OR (L55 OR L56))

=> s (l58 or l59 or l60 or l62) not l44
L91             3 (L58 OR L59 OR L60 OR L62) NOT L44

=> fil DRUGU, JICST-EPLUS, PASCAL, BIOTECHNO, ESBIOBASE, BIOSIS, BIOTECHDS, DISSABS, WPIDS

FILE 'DRUGU' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'JICST-EPLUS' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 16:21:09 ON 21 MAR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:21:09 ON 21 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'WPIDS' ENTERED AT 16:21:09 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> d que 186; d que 185; d que 187
```

previously printed

```
L66      226135 SEA LYMPHOMA# OR GERMINOBLASTOMA# OR RETICULOLYMPHOSARCOMA# OR
                GERMINOBLASTICSARCOMA#
L67           4 SEA (RETICULOLYMPHO OR RETICULO LYMPHO OR GERMINOBLAST? OR
                GERMINO BLAST?)(W) SARCOMA#
L68        1524 SEA MALIGNANT(A) HISTIOCYTOSIS
L69       11761 SEA PLASMACYTOMA#
L70        3530 SEA RETICULOENDOTHELIOSIS OR RETICULO ENDOTHELIOSIS
L71          84 SEA MAST CELL(2A) SARCOMA#
L72       36348 SEA MULTIPLE MYELOMA#
L73       96995 SEA HODGKIN? OR NONHODGKIN?
L74        6301 SEA TENASCIN# OR HEXABRACHION# OR CYTOTACTIN# OR BRACHONECTIN#
L76     1466398 SEA ANTIBOD?
L77       99404 SEA MAB#
L78      223185 SEA RADIOISOTOP?
L79      255610 SEA ISOTOP?
L80      115993 SEA RADIOLABEL?
L86          21 SEA (L66 OR L67 OR L68 OR L69 OR L70 OR L71 OR L72 OR L73) AND
                L74 AND (L76 OR L77) AND (L78 OR L79 OR L80)


L66      226135 SEA LYMPHOMA# OR GERMINOBLASTOMA# OR RETICULOLYMPHOSARCOMA# OR
                GERMINOBLASTICSARCOMA#
L67           4 SEA (RETICULOLYMPHO OR RETICULO LYMPHO OR GERMINOBLAST? OR
                GERMINO BLAST?)(W) SARCOMA#
L68        1524 SEA MALIGNANT(A) HISTIOCYTOSIS
L69       11761 SEA PLASMACYTOMA#
L70        3530 SEA RETICULOENDOTHELIOSIS OR RETICULO ENDOTHELIOSIS
L71          84 SEA MAST CELL(2A) SARCOMA#
L72       36348 SEA MULTIPLE MYELOMA#
L73       96995 SEA HODGKIN? OR NONHODGKIN?
L75         152 SEA 81C6
L78      223185 SEA RADIOISOTOP?
L79      255610 SEA ISOTOP?
L80      115993 SEA RADIOLABEL?
L85           6 SEA (L66 OR L67 OR L68 OR L69 OR L70 OR L71 OR L72 OR L73) AND
                L75 AND (L78 OR L79 OR L80)


L66      226135 SEA LYMPHOMA# OR GERMINOBLASTOMA# OR RETICULOLYMPHOSARCOMA# OR
                GERMINOBLASTICSARCOMA#
L67           4 SEA (RETICULOLYMPHO OR RETICULO LYMPHO OR GERMINOBLAST? OR
                GERMINO BLAST?)(W) SARCOMA#
L68        1524 SEA MALIGNANT(A) HISTIOCYTOSIS
L69       11761 SEA PLASMACYTOMA#
L70        3530 SEA RETICULOENDOTHELIOSIS OR RETICULO ENDOTHELIOSIS
L71          84 SEA MAST CELL(2A) SARCOMA#
L72       36348 SEA MULTIPLE MYELOMA#
L73       96995 SEA HODGKIN? OR NONHODGKIN?
L74        6301 SEA TENASCIN# OR HEXABRACHION# OR CYTOTACTIN# OR BRACHONECTIN#
L75         152 SEA 81C6
L81        5742 SEA IMMUNORADIOTHERAP? OR RADIOIMMUNOTHERAP? OR (IMMUNO(A)
                RADIO(A) THERAP?)
L82         965 SEA (RADIO OR RADIATION)(A)(CHIMER? OR CHIMAER?)
L87           6 SEA (L66 OR L67 OR L68 OR L69 OR L70 OR L71 OR L72 OR L73) AND
                (L74 OR L75) AND (L81 OR L82)

=> s (l86 or l85 or l87)  not l83

COMMAND INTERRUPTED
```

```
=> s (186 or 185 or 187)  not 183
COMMAND INTERRUPTED

=> s 186 not 183
L92          16 L86 NOT L83

=> s 185 not 183
L93           3 L85 NOT L83

=> s 187 not 183
L94           4 L87 NOT L83

=> s l92-l94
L95          19 (L92 OR L93 OR L94)

=> dup rem l89,l91,l95
FILE 'HCAPLUS' ENTERED AT 16:22:22 ON 21 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:22:22 ON 21 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'DRUGU' ENTERED AT 16:22:22 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHDS' ENTERED AT 16:22:22 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 16:22:22 ON 21 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION
PROCESSING COMPLETED FOR L89
PROCESSING COMPLETED FOR L91
PROCESSING COMPLETED FOR L95
L96          21 DUP REM L89 L91 L95 (14 DUPLICATES REMOVED)
                ANSWERS '1-13' FROM FILE HCAPLUS
                ANSWERS '14-16' FROM FILE EMBASE
                ANSWERS '17-18' FROM FILE DRUGU
                ANSWER '19' FROM FILE BIOTECHDS
                ANSWERS '20-21' FROM FILE WPIDS

=> d ibib ed abs hitind 1-13; d iall 14-21; fil hom

L96  ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2005:121072  HCAPLUS
DOCUMENT NUMBER:          142:217385
TITLE:                    Humanized and chimeric anti-CD19 antibodies,
                          fragments and conjugates for diagnosis and treatment
                          of B cell malignancies and autoimmune diseases
INVENTOR(S):              Hansen, Hans J.; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S):       Immunomedics, Inc., USA
SOURCE:                   PCT Int. Appl., 81 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     --------------       ----   --------    --------------------   --------
```

WO 2005012493 A2 20050210 WO 2004-US24636 20040802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-491282P P 20030731

ED Entered STN: 11 Feb 2005

AB The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.

IC ICM C12N

CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 8, 9, 63

ST humanized monoclonal **antibody** CD19 conjugate B cell malignancy; autoimmune disease B cell CD19 **antibody** diagnostic therapeutic conjugate

IT Interleukins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(21; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Leukemia
Lymphoma
(B-cell; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Disease, animal
(B-lymphocyte, malignancy; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Disease, animal
(B-lymphocyte; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD126; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD138; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD33; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD37; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Glycoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD40-L (antigen CD40 ligand); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD52; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DR4 (death receptor 4); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DR5 (death receptor 5); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Fibronectins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ED-B; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Kidney, disease
(Goodpasture's syndrome; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-DR; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HM1.24; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Purpura (disease)
(Henoch-Schoenlein's; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(I-A; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ICAM-1 (intercellular adhesion mol. 1); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Kidney, disease
(IgA nephropathy; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE type II; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG1; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCP (membrane cofactor protein); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NCA 66a; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NCA 66b; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NCA 66c; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NCA 66d; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAP (pokeweed antiviral protein), conjugates; humanized and chimeric

anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAP (pokeweed antiviral protein); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSEA-1 (stage-specific embryonic antigen 1); humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Serratia protease; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Brain, disease
(Sydenham's chorea; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T101; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Granulomatous disease
(Wegener's granulomatosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Imaging agents
(acoustic, enhancer; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Immunosuppressants
(adrenocortical; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Diagnosis
(agents, conjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Sulfonic acids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkanesulfonic, salts; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Nervous system, disease
(amyotrophic lateral sclerosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Inflammation
Spinal column, disease
(ankylosing spondylitis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Necrosis

(antigen; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Cytotoxic agents
(antimetabolites; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Artery, disease
Inflammation
(arteritis, Takayasu's; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Artery, disease
Inflammation
(arteritis, giant cell; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Skin, disease
(bullous pemphigoid; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carbohydrate-metabolizing, carbohydrate-cleaving; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Biology
(cell, host; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Multiple myeloma
(cell; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Infection
(chronic viral hepatitis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Reagents
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(clearing; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Drugs
(conjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Abrins
Ricins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Imaging agents
(contrast; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria, conjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Gamma ray
(emitting isotope; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxins, Pseudomonas; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enterotoxin A; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Blood vessel, disease
Skin, disease
(erythema nodosum; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exotoxins, Pseudomonas; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Lung, disease
(fibrosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Liposomes
(gas-filled; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Inflammation
Kidney, disease
(glomerulonephritis, rapidly progressive; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Addison's disease
Alkylating agents, biological
Angiogenesis inhibitors
Animal tissue culture
Antibiotics
Autoimmune disease
B cell (lymphocyte)
Canis familiaris
Color formers
Cytotoxic agents
DNA sequences
Dermatomyositis
Dermatomyositis
Diabetes mellitus
Domestic animal
Drug delivery systems
Dyes
Felis catus
Genetic vectors
Human
Immunomodulators
Labels
Lymphocyte
Mammalia
Molecular cloning
Multiple sclerosis
Mus musculus
Myasthenia gravis
Protein sequences
Pseudomonas
Psoriasis
Rheumatic fever
Rheumatoid arthritis
Sarcoidosis
Sjogren's syndrome
Staphylococcus
(humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Abrins
Alkaloids, biological studies
Anthracyclines
CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD5 (antigen)
CD8 (antigen)
CD80 (antigen)
CD80 (antigen)
Corticosteroids, biological studies
Cytokines
Enzymes, biological studies
Fusion proteins (chimeric proteins)
Gene, animal
Hemopoietins
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 2
Interleukin 3
Interleukin 6
Interleukin 6
Interleukins
Invariant chain (class II antigen)
Invariant chain (class II antigen)
Lymphotoxin
Nucleic acids
Oligonucleotides
Ricins
Stem cell factor
Tenascins
Toxins
Tumor necrosis factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Purpura (disease)
(idiopathic thrombocytopenic, acute and chronic; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis

and treatment of B cell malignancies and autoimmune diseases)

IT Drug delivery systems
(immunoconjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Diagnosis
(immunodiagnosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Drug delivery systems
(immunotoxins; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Apoptosis
Mitosis
(inhibitors; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Paramagnetic materials
(ions; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**label**; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Drug delivery systems
(liposomes; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Inflammation
Kidney, disease
(lupus nephritis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Animal cell
(mammalian; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Inflammation
Kidney, disease
(membranous glomerulonephritis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Erythema
(multiforme; humanized and chimeric anti-CD19 **antibodies**,

fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(necrosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Inflammation
Kidney, disease
(nephritis, post-streptococcal; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT **Lymphoma**
(non-Hodgkin's; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Metals, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-radioactive; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oncogene; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Genetic vectors
(pdHL2; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Skin, disease
(pemphigus vulgaris; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Artery, disease
Inflammation
(periarteritis nodosa; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Anemia (disease)
(pernicious anemia; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Chemicals
(photoactive; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Bone, disease
Inflammation
(polychondritis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Autoimmune disease
Endocrine system, disease
(polyglandular syndrome; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Muscle, disease
(polymyalgia rheumatica; humanized and chimeric anti-CD19

antibodies, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Myositis
(polymyositis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Biliary tract, disease
(primary biliary cirrhosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Fibrosis
(pulmonary; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Diagnosis
(radiodiagnostic agents; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporin; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporins, conjugates; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Connective tissue, disease
(scleroderma; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Lupus erythematosus
(systemic; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Infection
Nerve, disease
(tabes dorsalis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Thrombosis
(thromboangiitis obliterans; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Thyroid gland, disease
(thyrotoxicosis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Complement receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 2; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Inflammation
Intestine, disease
(ulcerative colitis; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Alkaloids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Hepatitis
(viral, chronic; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Interleukin 2 receptors
Interleukin 2 receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α chain; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 842984-78-5DP, conjugates 842984-80-9DP, conjugates 842984-82-1DP, conjugates 842984-84-3DP, conjugates
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 12585-85-2, Positron 12587-47-2, β-Ray
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(emitting isotope; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 380538-12-5 732296-31-0 805234-74-6 805234-75-7 805234-76-8 805234-77-9
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 50-35-1D, Thalidomide, derivs. 55-86-7, Nitrogen mustard 57-13-6D, Urea, substituted derivs. 59-30-3D, Folic acid, analogs 60-34-4D, Methyl hydrazine, derivs. 120-73-0D, Purine, analogs 151-56-4D, Ethylenimine, derivs. 289-95-2D, Pyrimidine, analogs 1605-68-1D, Taxane, derivs. 4375-07-9D, Epipodophyllotoxin, derivs. 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-06-4D, Platinum, coordination compds. 7440-54-2, Gadolinium, biological studies 7689-03-4D, Camptothecin, derivs. 9001-78-9D, Alkaline phosphatase, **antibody** conjugates 9001-99-4D, Ribonuclease, **antibody** conjugates 9003-98-9D, DNase I, **antibody** conjugates 9004-08-4D, Cathepsin, **antibody** conjugates 9014-01-1D, Subtilisin, **antibody** conjugates 9014-06-6D, **antibody** conjugates 9014-42-0D, Thrombopoietin, **antibody** conjugates 9016-17-5D, Arylsulfatase, **antibody** conjugates 9025-05-2D, Cytosine deaminase, **antibody** conjugates 9031-96-3D, Peptidase, **antibody** conjugates 9031-98-5D, Carboxypeptidase, **antibody** conjugates 9073-60-3D, **antibody** conjugates 9073-78-3D, Thermolysin, **antibody** conjugates 9077-67-2D, D-Alanine Carboxypeptidase, **antibody** conjugates 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11096-26-7D, Erythropoietin, **antibody** conjugates 13010-20-3D, Nitrosourea, derivs. 13981-22-1, Nitrogen-13, biological studies 13981-25-4, Copper-64, biological studies 13981-56-1, Fluorine-18, biological studies 13982-43-9, Oxygen-15, biological studies 14119-09-6, Gallium-67, biological studies 14158-30-6, Iodine-124, biological studies 14158-31-7, Iodine-125, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14276-53-0, Copper-62, biological studies 14333-33-6, Carbon-11, biological studies 14378-26-8, Rhenium-188, biological studies 14596-37-3, Phosphorus-32, biological studies 14809-53-1, Yttrium-86, biological studies 14913-49-6, Bismuth-212, biological studies 14998-63-1, Rhenium-186, biological studies 15056-34-5D, Triazene, derivs. 15715-08-9, Iodine-123, biological studies 15750-15-9, Indium-111, biological studies 15755-39-2, Astatine-211, biological studies 15757-14-9, Gallium-68, biological studies 15757-86-5, Copper-67, biological studies 15765-38-5, Bromine-76, biological studies 15776-20-2, Bismuth-213, biological studies 23214-92-8D, Doxorubicin, analogs 33069-62-4D, Taxol, derivs. 62683-29-8, Colony-stimulating factor 75037-46-6D, Gelonin, **antibody** conjugates 83869-56-1D, GM-CSF, **antibody** conjugates 109675-94-7, Placental growth factor 127464-60-2, VEGF 143011-72-7D, G-CSF, **antibody** conjugates 187888-07-9, Endostatin 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 140879-24-9, Proteasome 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 842982-52-9DP, conjugates 842984-79-6DP, conjugates 842984-81-0DP, conjugates 842984-83-2DP, conjugates
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; humanized and chimeric anti-CD19

antibodies, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 9001-92-7D, Proteinase, **antibody** conjugates
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protease; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 842988-53-8
RL: PRP (Properties)
(unclaimed protein sequence; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

IT 842988-42-5 842988-43-6 842988-44-7 842988-45-8 842988-46-9
842988-47-0 842988-48-1 842988-49-2 842988-50-5 842988-51-6
842988-52-7 842988-54-9, 2: PN: WO2005012493 unclaimed sequence
842988-55-0, 3: PN: WO2005012493 unclaimed sequence
RL: PRP (Properties)
(unclaimed sequence; humanized and chimeric anti-CD19 **antibodies**, fragments and conjugates for diagnosis and treatment of B cell malignancies and autoimmune diseases)

L96 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:934484 HCAPLUS
DOCUMENT NUMBER: 141:409779
TITLE: Polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiological disorder and autoimmune disease
INVENTOR(S): Rossi, Edmund A.; Chang, Chien-Hsing; McBride, William J.
PATENT ASSIGNEE(S): IBC Pharmaceuticals, USA; Immunomedics, Inc
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004094613	A2	20041104	WO 2004-US12662		20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2005003403	A1	20050106	US 2004-829388		20040422
PRIORITY APPLN. INFO.:			US 2003-464532P	P	20030422
			US 2003-525391P	P	20031124

ED Entered STN: 06 Nov 2004
AB The invention provides for a polyvalent protein complex (PPC) comprising two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 'v-regions', which comprise amino acid sequences capable of forming an antigen binding site when

matched with a corresponding v-region on the opposite polypeptide chain. Up to about 6 'v-regions' can be used on each polypeptide, chain. The v-regions of each polypeptide chain are connected linearly to one another and may be connected by interspersed linking regions. When arranged in the form of the PPC, the v-regions on each polypeptide chain form individual antigen binding sites.

IC ICM C12N

CC 15-3 (Immunochemistry)
Section cross-reference(s): 3, 9, 63

IT Autoimmune disease
(B cell; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Leukemia
Lymphoma
(B-cell; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(BS14HP; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD33; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CSAp or colon-specific antigen-p; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-A3; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-DR; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Purpura (disease)
(Henoch-Schoenlein's; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(I-A; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Kidney, disease
(IgA nephropathy; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE type II; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KS-1; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ley; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAA (melanoma-associated antigen); polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAGE (melanoma antigen-encoding gene); polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC2; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC3; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC4; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NCA66; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Imaging
(NMR; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAM-4; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSMA; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Calcium-binding proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S-100; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Cough
(Sydenham's chorea; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T101; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TAG-72 (tumor-associated glycoprotein 72); polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and

conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Granulomatous disease
(Wegener's granulomatosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Imaging
(acoustic; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Lymphocyte
Macrophage
Monocyte
Polymorphonuclear leukocyte
(activated; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Purification
(affinity; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Sulfonic acids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkanesulfonic, salts; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Nervous system, disease
(amyotrophic lateral sclerosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-idiotypic; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Estrogens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiestrogens; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Carcinoma
Leukemia
Lymphoma
Necrosis
Neuroglia, neoplasm
Sarcoma
(antigen; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Artery, disease
Inflammation
(arteritis, Takayasu's; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Artery, disease
Inflammation
(arteritis, giant cell; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Allergy
(atopy; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Infection
(bacterial; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bispecific; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Skin, disease
(bullous pemphigoid; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Diagnosis
(cancer; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Ischemia
(cardiac; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Drug delivery systems
(carriers; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Biology
(cell, host; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Infection
(chronic active hepatitis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(complexes, polyvalent; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Immunity
(disorder, B cell; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Imaging agents
(enhancer; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Blood vessel, disease
Skin, disease
(erythema nodosum; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Lung, disease
(fibrosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(folate; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Liposomes
(gas-filled; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Inflammation

Kidney, disease
(glomerulonephritis, rapidly progressive; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hBS14; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Parvo-like virus
(human serum; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Purpura (disease)
(idiopathic thrombocytopenic, acute and chronic; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Drug delivery systems
(immunoconjugates; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Diagnosis
(immunodiagnosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Immunoassay
(immunol. staining; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Drug delivery systems
(immunotoxins; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Heart, disease
(infarction; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Parasite
(infection; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Microorganism

Pathogen
(infectious; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Heart, disease
(ischemia; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(linker; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Membrane, biological
(lipid; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Drug delivery systems
(liposomes; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Inflammation
Kidney, disease
(lupus nephritis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Animal cell
(mammalian; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Inflammation
Kidney, disease
(membranous glomerulonephritis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Erythema
(multiforme; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis

and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multispecific; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Animal cell line
(murine myeloma; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(necrosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Inflammation
Kidney, disease
(nephritis, post-streptococcal; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Chloramines
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrogen mustards; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Drug delivery systems
(parenterals; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Plasmids
(pdHL2; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Skin, disease
(pemphigus vulgaris; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Linking agents
(peptide; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Anemia (disease)
(pernicious anemia; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Bone, disease
Inflammation

(polychondritis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Autoimmune disease
Endocrine system, disease
(polyglandular syndrome; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Disease, animal
(polymyalgia; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Myositis
(polymyositis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Addison's disease
Alzheimer's disease
Antibiotics
Antitumor agents
Atherosclerosis
Bacillus anthracis
Blastomyces dermatitidis
Blood serum
Bluetongue virus
Brucella melitensis
Candida albicans
Coccidioides immitis
Combination chemotherapy
Cosmids
Cryptococcus neoformans
Cytomegalovirus
DNA sequences
Dengue virus
Dermatomyositis
Diabetes mellitus
Drugs
Epidermophyton
Epitopes
Escherichia coli
Feline leukemia virus
Hepatitis B virus
Herpesviridae
Histoplasma capsulatum
Human
Human T-lymphotropic virus
Human adenovirus
Human herpesvirus
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human poliovirus
Immunoassay
Immunotherapy
Infection
Inflammation
Influenza virus
Labels

Legionella pneumophila
Lyme disease
Lymphocytic choriomeningitis virus
Malaria
Measles virus
Microsporum
Molecular cloning
Mouse mammary tumor virus
Multiple myeloma
Multiple sclerosis
Mumps virus
Murine leukemia virus
Myasthenia gravis
Mycobacterium leprae
Mycobacterium tuberculosis
Mycoplasma
Mycosis
Neisseria gonorrhoeae
Neisseria meningitidis
Plant cell
Plasmids
Positron-emission tomography
Protein sequences
Pseudomonas aeruginosa
Psoriasis
Rabies virus
Reoviridae
Respiratory syncytial virus
Rheumatic fever
Rheumatoid arthritis
Rodentia
Rubella virus
Sarcoidosis
Sendai virus
Simian virus 40
Sindbis virus
Single-photon-emission computed tomography
Sjogren's syndrome
Spirochaeta
Sporothrix schenckii
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Tomography
Transplant rejection
Treponema pallidum
Trichophyton
Vesicular stomatitis virus
Yeast
(polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyvalent protein complexes including trivalent bispecific chimeric

antibodies and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Androgens
CA 125 (carbohydrate antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD30 (antigen)
CD45 (antigen)
CD80 (antigen)
Carcinoembryonic antigen
Cytokines
Enzymes, biological studies
Epidermal growth factor receptors
Estrogens
Growth factors, animal
Haptens
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 2
Interleukin 3
Interleukin 6
Invariant chain (class II antigen)
Lymphokines
Metals, biological studies
Nucleic acids
Progestogens
Prostate-specific antigen
Radionuclides, biological studies
Steroids, biological studies
Tenascins
Toxins
neu (receptor)
α-Fetoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Biliary tract, disease
(primary biliary cirrhosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Drug delivery systems
(prodrugs; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Fibrosis
(pulmonary; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Proteins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant, chimeric; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Proteins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Connective tissue, disease
(scleroderma; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppressants and antagonists; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Lupus erythematosus
(systemic; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Infection
Nerve, disease
(tabes dorsalis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Thrombosis
(thromboangiitis obliterans; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Thyroid gland, disease
(thyrotoxicosis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated, EGP-1; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated, EGP-2; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-specific antigens; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Complement receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 2; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Haemophilus influenzae
(type b; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Inflammation
Intestine, disease
(ulcerative colitis; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Alkaloids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Hepatitis
(viral, chronic active; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Infection
(viral; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Wart
(virus; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Animal virus
(wart; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α chain; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT 790727-14-9P 790793-15-6P 790793-18-9P 790793-19-0P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid seqence; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT 790793-16-7P 790793-17-8P 790793-20-3P 790793-21-4P 790793-22-5P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-13-6D, Urea, substituted derivs. 57-22-7, Vincristine 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-05-9, Leucovorin 59-05-2, Methotrexate 59-30-3D, Folic acid, analogs 60-34-4D, Methylhydrazine, derivs. 66-75-1, Uracil mustard 70-47-3, L-Asparagine, biological studies 71-58-9, Medroprogesterone acetate 76-43-7, Fluoxymesterone 120-73-0D, Purine, analogs 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 151-56-4D, Ethylenimine, derivs. 154-42-7, Thioguanine 154-93-8, Carmustine 289-95-2D, Pyrimidine, analogs 305-03-3, Chlorambucil 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 671-16-9, Procarbazine 865-21-4, Vinblastine 1404-00-8, Mitomycin 1605-68-1D, Taxane, derivs. 2169-64-4, Azaribine 4342-03-4, Dacarbazine 4346-18-3, Phenyl butyrate 7429-91-6, Dysprosium, biological studies 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-00-8, Neodymium, biological studies 7440-02-0, Nickel, biological studies 7440-06-4D, Platinum, coordination complexes 7440-19-9, Samarium, biological studies 7440-27-9, Terbium, biological

studies 7440-47-3, Chromium, biological studies 7440-48-4, Cobalt, biological studies 7440-50-8, Copper, biological studies 7440-52-0, Erbium, biological studies 7440-54-2, Gadolinium, biological studies 7440-60-0, Holmium, biological studies 7440-62-2, Vanadium, biological studies 7440-64-4, Ytterbium, biological studies 9002-61-3, Human chorionic gonadotropin 9014-42-0, Thrombopoietin 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 11096-26-7, Erythropoietin 13010-20-3, Nitrosourea 13010-47-4, Lomustine 13909-09-6, Semustine 13967-65-2, Holmium-166, biological studies 13981-25-4, Copper-64, biological studies 13981-27-6, Zirconium-89, biological studies 13981-56-1, Fluorine-18, biological studies 14093-04-0, Iron-52, biological studies 14119-09-6, Gallium-67, biological studies 14158-30-6, Iodine-124, biological studies 14158-31-7, Iodine-125, biological studies 14191-64-1, Praseodymium-142, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14276-53-0, Copper-62, biological studies 14333-34-7, Gadolinium-155, biological studies 14378-26-8, Rhenium-188, biological studies 14391-19-6, Terbium-161, biological studies 14391-32-3, Gadolinium-157, biological studies 14391-96-9, Scandium-47, biological studies 14392-07-5, Gadolinium-156, biological studies 14596-37-3, Phosphorus-32, biological studies 14683-24-0, Gadolinium-154, biological studies 14809-53-1, Yttrium-86, biological studies 14809-55-3, Technetium-94, biological studies 14913-49-6, Bismuth-212, biological studies 14998-63-1, Rhenium-186, biological studies 15056-34-5D, Triazene, derivs. 15068-71-0, Gadolinium-158, biological studies 15092-94-1, Lead-212, biological studies 15438-31-0, Ferrous ion, biological studies 15623-45-7, Radium-223, biological studies 15663-27-1, Cisplatin 15715-08-9, Iodine-123, biological studies 15749-66-3, Phosphorus-33, biological studies 15750-15-9, Indium-111, biological studies 15755-39-2, Astatine-211, biological studies 15757-14-9, Gallium-68, biological studies 15757-86-5, Copper-67, biological studies 15760-04-0, Silver-111, biological studies 15766-00-4, Samarium-153, biological studies 15776-20-2, Bismuth-213, biological studies 15840-01-4, Dysprosium-166, biological studies 18378-89-7, Mithramycin 18883-66-4, Streptozocin 20074-52-6, Ferric ion, biological studies 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 33069-62-4, Taxol 33419-42-0, Etoposide 61912-98-9, Insulin-like growth factor 62683-29-8, Colony-stimulating factor 83314-01-6, Bryostatin-1 83869-56-1, GM-CSF 95058-81-4, Gemcitabine 100286-90-6, CPT-11 127464-60-2, Vascular endothelial growth factor 143011-72-7, G-CSF 192382-42-6, Histamine-succinyl-glycine 352423-07-5, Placenta growth factor 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies 391267-27-9, IMP 241 608489-42-5, IMP 245
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

IT 790794-20-6 790794-21-7 790794-22-8 790794-23-9 790794-24-0
RL: PRP (Properties)
(unclaimed nucleotide sequence; polyvalent protein complexes including trivalent bispecific chimeric **antibodies** and conjugates for diagnosis and treatment of cancer, infection, cardiol. disorder and autoimmune disease)

L96 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:902115 HCAPLUS
DOCUMENT NUMBER: 141:384388
TITLE: Morpholino imaging and therapy via amplification

targeting

INVENTOR(S): Hnatowich, Donald J.; He, Jiang; Liu, Guozheng; Gupta, Suresh; Zhang, Yumin; Rusckowski, Mary
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091525	A2	20041028	WO 2004-US11517	20040415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-462692P P 20030415
ED Entered STN: 28 Oct 2004
AB The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathol. condition. The kit comprises, in sep. containers, (A) a first conjugate comprising a targeting moiety and a morpholino oligomer (MORF), wherein said targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (B) optionally, a clearing agent; (C) a second conjugate comprising multiple copies of complementary morpholino oligomer (cMORF) and a diagnostic agent or therapeutic agent; wherein the CMORF is bound to a polymer; and (D) a third conjugate comprising a MORF and a radiolabel. The method for targeting of a diagnostic or therapeutic agent comprises administering (A), optionally (B), (C) and (D) to a mammal. For example, whole body images obtained simultaneously of three nude mice each bearing LS174T tumors were presented. The first animal received MORF-99mTc (3 h before imaging), the second one received MORF-99mTc and the cMORF-polymer (21 h before imaging), while the study animal (amplification) received the MORF-99mTc, cMORF-polymer, and the anti-CEA antibody (MN14)-MORF (51 h before imaging). The images show tumor only in the study animals receiving both the antibody and the polymer, providing evidence that in vivo amplification targeting is feasible and has been achieved.
IC ICM A61K
CC 63-8 (Pharmaceuticals)
Section cross-reference(s): 2, 8, 15
ST morpholino oligomer conjugate diagnostic therapeutic targeting kit; **antibody** polymer morpholino oligomer conjugate targeting kit
IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IgG1, MN14, conjugates with DTPA or morpholino oligomer, **radiolabeled**; kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)
IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)
(fragments; kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)

IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized; kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)

IT Antitumor agents
Autoimmune disease
Chelating agents
Dyes
Fluorescent substances
Human
Immunomodulators
Infection
Inflammation
Lymphoma
(kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)

IT **Antibodies** and Immunoglobulins
Cytokines
Enzymes, biological studies
Hormones, animal, biological studies
Neurotransmitters
Oligomers
Oligonucleotides
Peptides, biological studies
Proteins
Radionuclides, biological studies
Steroids, biological studies
Toxins
Vitamins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)

IT Antigens
CD19 (antigen)
CD22 (antigen)
CD40 (antigen)
Carcinoembryonic antigen
Interleukin 15
Interleukin 6
Invariant chain (class II antigen)
Prostate-specific antigen
Tenascins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(targeting of; kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)

IT 25104-18-1DP, Polylysine, conjugates with morpholino oligomers
25104-18-1DP, Polylysine, succinylated, conjugates with morpholino oligomer, **radiolabeled** 38000-06-5DP, Polylysine, conjugates with morpholino oligomers 38000-06-5DP, Polylysine, succinylated, conjugates with morpholino oligomer, **radiolabeled**
616900-87-9DP, conjugates with **antibody** or DTPA, **radiolabeled** 616900-88-0DP, conjugates with succinylated polylysine, **radiolabeled**
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kits for amplification targeting of diagnostic or therapeutic agent

using morpholino oligomer conjugated to polymer)
IT 67-43-6DP, DTPA, conjugates with **antibody** or morpholino oligomer, **radiolabeled** 66516-09-4DP, MAG 3, conjugates with morpholino oligomer, **radiolabeled**
RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(kits for amplification targeting of diagnostic or therapeutic agent using morpholino oligomer conjugated to polymer)

L96 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2004:606473 HCAPLUS
DOCUMENT NUMBER: 141:156960
TITLE: Methods for obtaining porphyrin derivatives, and use thereof in radioimmunotherapy
INVENTOR(S): Boitrel, Bernard Philippe Albert
PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique, Fr.; Universite De Rennes 1
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063199	A1	20040729	WO 2003-FR3794	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2849035	A1	20040625	FR 2002-16371	20021220
PRIORITY APPLN. INFO.:			FR 2002-16371 A	20021220
			FR 2003-12341 A	20031022

OTHER SOURCE(S): MARPAT 141:156960
ED Entered STN: 29 Jul 2004
GI



I

AB The invention concerns compds. I [wherein A forms a chain with C, called A-C chain, X-Y-C6H4-(CH2)n1-C(Z,W)-(CH2)n2-C6H4-Y-X-, then B forms a chain with D, said chain above, called A-C and B-D chains located independently of each other, above (position α) or below (position β) of the porphyrin macrocycle; or when A forms a chain with D, called A-D chain of above formula , then B forms a chain with C, called B-C chain of above formula, one of said A-D or B-C chains, being located above (position α) of the plane of the porphyrin macrocycle while the other A-D or B-C chain is located below (position β) of the porphyrin macrocycle; when X = NH, O, CO, CH2, Y = CO, CH2, NH, O, resp.; n1, n2 = 1 - 3; U = C(Z,W), N(CHRaCO2Rb); Z = CN, NO2, CO2-, CH2NR1R2, SO3R3, SO2R3; R1, R2 = H, (un)branched C1-8-alkyl, cycloalkyl, aryl, alkylaryl; R3 = H, alkaline metal (especially, Na, K), NR4R5; R4, R5 = (un)branched C1-8-alkyl, cycloalkyl, p-nitroaryl; W = CO2-, CO2R6; R6 = H, (un)branched C1-8-alkyl, cycloalkyl, aryl, alc., p-nitrophenol; CZW = Meldrum's acid; Ra = R1, amino acid; Rb = R1; EF, GH = CH:CH, CH2CH2]. Thus, macrocycle α,α,β,β-I [2-AC-2' = 2''-BD-2''' = 3-NHCOC6H4CH2C(CO2Et)2CH2C6H4CONH-3; EF = GH = CH:CH] was prepared from TAPP-α,α,β,β via N-acylation with 3-(ClCH2)C6H4COCl, followed by alkylation of CH2(CO2Et)2; the nickel and zinc salts of II were also prepared The invention also concerns complexes between said compds. and radioelements, and pharmaceutical compns. containing said complexes.

IC ICM C07D487-22
ICS A61K051-00; A61K049-00; A61K031-409; A61P035-00

CC 26-7 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63

IT **Lymphoma**
Neoplasm
(medicinals; preparation of porphyrin derivs. and their complexes with radioelements for use in radioimmunotherapy)

IT **Lymphoma**
(non-Hodgkin's, medicinals; preparation of porphyrin derivs. and their complexes with radioelements for use in radioimmunotherapy)

IT Antigens
CD20 (antigen)
CD22 (antigen)
Epidermal growth factor receptors
Tenascins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathologies related to, medicinals for; preparation of porphyrin derivs. and their complexes with radioelements for use in radioimmunotherapy)
IT Antitumor agents
Immunoradiotherapy
(preparation of porphyrin derivs. and their complexes with radioelements for use in radioimmunotherapy)

L96 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2004:565117 HCAPLUS
DOCUMENT NUMBER: 141:122334
TITLE: Immunotherapy of B cell malignancies and autoimmune disease using unconjugated and conjugated **antibodies**, fragments or fusion proteins
INVENTOR(S): Goldenberg, David M.; Hansen, Hans
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; Mccall, John Douglas
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058298	A1	20040715	WO 2003-GB5700	20031231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004219156	A1	20041104	US 2003-747199	20031230
PRIORITY APPLN. INFO.:			US 2002-437145P P	20021231

ED Entered STN: 15 Jul 2004
AB The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed. The target antigen of the unconjugated and conjugated antibody is CD3, CD4, CD5, CD8, CD11c, CD14, CD15, CD19, CD20, CD21, CD22, CD23, CD25, CD33, CD37, CD38, CD40, CD40L, CD46, CD52, CD54, CD74, CD80, CD126, MUC1, tenascin, Ia, HMI.24, HLA-DR and tumor antigen. The antibody is human, murine, chimeric, primatized or humanized antibody. The antibody is conjugated with therapeutic agent selected from drug, toxin, immunomodulator, chelator, boron compound, photoactive agent or radionuclide.
IC ICM A61K039-00
ICS A61K041-00; A61K051-10; A61K039-395; A61P005-00; A61P037-06
CC 15-3 (Immunochemistry)
Section cross-reference(s): 9, 63

ST immunotherapy B cell malignancy autoimmune disease conjugate unconjugate **antibody**

IT **Lymphoma**
(B-cell; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Disease, animal
(B-lymphocyte, malignancy; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD11C; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD126; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD33; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD37; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Glycoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD40-L (antigen CD40 ligand); unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD52; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Kidney, disease
(Goodpasture's syndrome; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-DR; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMI.24; unconjugated and conjugated **antibodies**, fragments or

antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Purpura (disease)
(Henoch-Schoenlein's; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(I-A; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ICAM-1 (intercellular adhesion mol. 1); unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Kidney, disease
(IgA nephropathy; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE type II; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCP (membrane cofactor protein); unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAP (pokeweed antiviral protein); unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Stem cell factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S1 factor; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Antigens

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSEA-1 (stage-specific embryonic antigen 1); unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Brain, disease
(Sydenham's chorea; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Leukemia
(T-cell; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Disease, animal
(T-lymphocyte; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Lymphoproliferative disorders
(Waldenstrom's macroglobulinemia; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Granulomatous disease
(Wegener's granulomatosis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Leukemia
(acute lymphocytic; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Sulfonic acids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkanesulfonic, salts; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Nervous system, disease
(amyotrophic lateral sclerosis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Inflammation
Spinal column, disease
(ankylosing spondylitis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Cytotoxic agents
(antimetabolites; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Artery, disease
Inflammation
(arteritis, Takayasu's; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Artery, disease
Inflammation
(arteritis, giant cell; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Autoimmune disease
Inflammation
Thyroid gland, disease
(autoimmune thyroiditis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Skin, disease
(bullous pemphigoid; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Leukemia
(chronic lymphocytic; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Infection
(chronic viral hepatitis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT T cell (lymphocyte)
(disease; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Blood vessel
(endothelium, antigen; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enterotoxin A, Staphylococcal; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enterotoxins, staphylococcal A; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(exotoxins, Pseudomonas; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Lung, disease
(fibrosis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fragments; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Mycosis
(fungoides; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Inflammation
Kidney, disease
(glomerulonephritis, rapidly progressive; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Purpura (disease)
(idiopathic thrombocytopenic, acute and chronic; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Drug delivery systems
(immunoconjugates; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Diagnosis
(immunodiagnosis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Drug delivery systems
(immunotoxins; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Apoptosis
(inducer; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Mitosis
(inhibitors; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Fluorescent substances
(**label**; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Heavy metals
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**label**; unconjugated and conjugated **antibodies**,

fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Inflammation
Kidney, disease
(lupus nephritis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Inflammation
Kidney, disease
(membranous glomerulonephritis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Erythema
(multiforme; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Skin, neoplasm
(mycosis fungoides; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Inflammation
Kidney, disease
(nephritis, post-streptococcal; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Erythema
(nodosum; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT **Lymphoma**
(non-Hodgkin's; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Drug delivery systems
(parenterals; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Skin, disease
(pemphigus vulgaris; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Artery, disease
Inflammation
(periarteritis nodosa; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Anemia (disease)
(pernicious anemia; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Chemicals
(photoactive; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Bone, disease
Inflammation
(polychondritis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Autoimmune disease
Endocrine system, disease
(polyglandular syndrome; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Muscle, disease
(polymyalgia rheumatica; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Myositis
(polymyositis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Biliary tract, disease
(primary biliary cirrhosis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primatized; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Fibrosis
(pulmonary; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporin; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Connective tissue, disease
(scleroderma; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppressant; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Lupus erythematosus
(systemic; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Infection
Nerve, disease
(tabes dorsalis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Thrombosis
(thromboangiitis obliterans; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune

disease)
IT Thyroid gland, disease
(thyrotoxicosis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Heavy metals
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toxicity, **label**; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Complement receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 2; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Inflammation
Intestine, disease
(ulcerative colitis; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)
IT Addison's disease
Alkylating agents, biological
Angiogenesis inhibitors
Antibiotics
Autoimmune disease
Chelating agents
Color formers
Cytotoxic agents
Dermatomyositis
Diabetes mellitus
Domestic animal
Drug delivery systems
Drugs
Dyes
Human
Immunomodulators
Immunotherapy
Labels
Lymphoma
Mammalia
Multiple myeloma
Multiple sclerosis
Myasthenia gravis
Pet animal
Photodynamic therapy
Primates
Pseudomonas
Psoriasis
Rheumatic fever
Rheumatoid arthritis
Rodentia
Sarcoidosis
Sjogren's syndrome

Veterinary medicine
(unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Abrins
Alkaloids, biological studies
Anthracyclines
Antibodies and Immunoglobulins
CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD3 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD5 (antigen)
CD8 (antigen)
CD80 (antigen)
Coordination compounds
Cytokines
Enzymes, biological studies
Fusion proteins (chimeric proteins)
Hemopoietins
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Invariant chain (class II antigen)
Lymphotoxin
Peptides, biological studies
Radionuclides, biological studies
Ricins
Tenascins
Toxins
Tumor necrosis factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Endothelium
(vascular, antigen; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Hepatitis
(viral, chronic; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α chain; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α-; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Integrins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(αX; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT 12586-31-1, Neutron
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(capture; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT 329900-75-6, Cyclooxygenase 2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 53-03-2, Prednisone 55-86-7D, Nitrogen mustard, analogs 57-13-6D, Urea, substituted derivs. and analogs 57-22-7, Vincristine 58-05-9, Leucovorin 59-05-2, Methotrexate 59-30-3D, Folic acid, derivs. and analogs 60-34-4D, Methylhydrazine, derivs. and analogs 67-43-6, DTPA 120-73-0D, Purine, derivs. and analogs 151-56-4D, Ethylenimine, derivs. and analogs 154-93-8, Carmustine 289-95-2D, Pyrimidine, derivs. and analogs 671-16-9, Procarbazine 1605-68-1D, Taxane, derivs. and analogs 4346-18-3, Phenyl butyrate 4375-07-9, Epipodophyllotoxin 7429-90-5D, Aluminum, complexes 7439-94-3D, Lutetium, complexes 7440-05-3D, Palladium, complexes 7440-06-4D, Platinum, coordination complexes and analogs 7440-42-8D, Boron, compds. 7440-55-3D, Gallium, complexes 7440-66-6D, Zinc, complexes 7689-03-4D, Camptothecin, derivs. and analogs 9001-99-4, RNase 9003-98-9, DNase I 9014-42-0, Thrombopoietin 10043-49-9, Gold-198, biological studies 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11056-06-7, Bleomycin 11096-26-7, Erythropoietin 13010-20-3D, Nitrosourea, derivs. and analogs 13967-65-2, Holmium-166, biological studies 13981-25-4, Copper-64, biological studies 13981-38-9, Cobalt-58, biological studies 14119-09-6, Gallium-67, biological studies 14119-15-4, Molybdenum-99, biological studies 14158-27-1, Strontium-89, biological studies 14158-31-7, Iodine-125, biological studies 14158-35-1, Iridium-194, biological studies 14191-64-1, Praseodymium-142, biological studies 14265-71-5,

Selenium-75, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14378-26-8, Rhenium-188, biological studies 14391-11-8, Gold-199, biological studies 14391-19-6, Terbium-161, biological studies 14391-20-9, Holmium-161, biological studies 14391-32-3, Gadolinium-157, biological studies 14391-96-9, Scandium-47, biological studies 14596-12-4, Iron-59, biological studies 14596-37-3, Phosphorus-32, biological studies 14687-61-7, Arsenic-77, biological studies 14694-69-0, Iridium-192, biological studies 14798-12-0, Boron-10, biological studies 14835-02-0, Radon-219, biological studies 14913-49-6, Bismuth-212, biological studies 14913-89-4, biological studies 14914-68-2, Antimony-119, biological studies 14981-64-7, Palladium-109, biological studies 14981-79-4, Praseodymium-143, biological studies 15056-34-5D, Triazene, derivs. and analogs 15092-94-1, Lead-212, biological studies 15117-96-1, Uranium-235, biological studies 15229-37-5, Bismuth-211, biological studies 15623-45-7, Radium-223, biological studies 15706-52-2, Polonium-215, biological studies 15749-66-3, Phosphorus-33, biological studies 15750-15-9, Indium-111, biological studies 15750-24-0, Fermium-255, biological studies 15755-39-2, Astatine-211, biological studies 15756-41-9, Francium-221, biological studies 15757-86-5, Copper-67, biological studies 15760-04-0, Silver-111, biological studies 15765-31-8, Promethium-149, biological studies 15765-78-3, Rhenium-189, biological studies 15766-00-4, Samarium-153, biological studies 15776-20-2, Bismuth-213, biological studies 15816-77-0, Lead-211, biological studies 15840-13-8, Erbium-169, biological studies 15904-62-8, Dysprosium-152, biological studies 17239-90-6, Astatine-217, biological studies 23214-92-8D, Doxorubicin, derivs. and analogs 33069-62-4D, Taxol, derivs. and analogs 33419-42-0, Etoposide 56491-86-2, NOTA 60239-18-1, DOTA 60239-22-7, TETA 62683-29-8, Colony stimulating factor 75037-46-6, Gelonin 83314-01-6, Bryostatin-1 83869-56-1, GM-CSF 127464-60-2, Vascular endothelial growth factor 138612-85-8, Platinum-109 143011-72-7, G-CSF 187888-07-9D, Endostatin, derivs. and analogs 352423-07-5, Placenta growth factor 378253-43-1, Bromine-80m, biological studies 378782-88-8, Osmium-189m, biological studies 378784-00-0, Rhodium-103m, biological studies 378784-45-3, Technetium-99m, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unconjugated and conjugated **antibodies**, fragments or **antibody** fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease)

L96 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2004:934160 HCAPLUS
DOCUMENT NUMBER: 141:388650
TITLE: Anti-CD74 immunoconjugates and their therapeutic and diagnostic uses
INVENTOR(S): Griffiths, Gary L.; Hansen, Hans J.; Goldenberg, David M.; Lundberg, Bo B.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 377,122.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004219203	A1	20041104	US 2003-706852	20031112
US 6306393	B1	20011023	US 1999-307816	19990510

US 2002071807	A1	20020613	US 2001-965796	20011001
US 2003124058	A1	20030703	US 2002-314330	20021209
US 2003133930	A1	20030717	US 2003-350096	20030124
US 2004115193	A1	20040617	US 2003-377122	20030303
WO 2004110390	A2	20041223	WO 2004-US19238	20040617

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1999-307816	A1	19990510
US 2000-590284	A1	20000609
US 2001-965796	A1	20011001
US 2002-360259P	P	20020301
US 2002-314330	A2	20021209
US 2003-350096	A2	20030124
US 2003-377122	A2	20030303
US 2003-478830P	P	20030617
US 1997-41506P	P	19970324
US 1998-38995	A2	19980312
US 1999-138284P	P	19990609
US 2003-706852	A	20031112

ED Entered STN: 06 Nov 2004

AB Disclosed are compns. that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compns. may be part of a kit for administering the anti-CD74 immunoconjugates compns. in therapeutic and/or diagnostic methods. Anti-CD74 binding mols. are conjugated to the one or more lipids by one or more of a sulfide linkage, a hydrazone linkage, a hydrazine linkage, an ester linkage, an amido linkage, an amino linkage, an imino linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, a carbon-carbon linkage. Anti-CD74 immunoconjugates comprise a drug, a prodrug, a toxin, an enzyme, a radioisotope, an immunomodulator, a cytokine, a hormone, an antibody., an oligonucleotide, or a photodynamic agent.

IC ICM A61K039-395
ICS A61K009-127

NCL 424450000; 424144100

CC 1-6 (Pharmacology)
Section cross-reference(s): 8, 15

IT **Lymphoma**
(B-cell, diagnosis and treatment of; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD33, **antibody** for; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HLA-DR, **antibody** for; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG1, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG2, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG3, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG4, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Lymphoma**
(T-cell, diagnosis and treatment of; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT Human
(anti-CD74 **antibody**; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT Angiogenesis inhibitors
Antitumor agents
Cations
Endoscopes
Imaging agents
Immunomodulators
Immunoradiotherapy
Photodynamic therapy
Photosensitizers (pharmaceutical)
Positron-emission tomography
Test kits
Tomography
X-ray
(anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chimeric, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT Autoimmune disease
Carcinoma
Hodgkin's disease
Melanoma
Multiple myeloma
Neuroglia, neoplasm
Ovary, neoplasm
Prostate gland, neoplasm
Sarcoma
Transplant rejection
(diagnosis and treatment of; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fragments, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fusion products, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heavy chain, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(humanized, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD30 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD5 (antigen)
CD8 (antigen)
CD80 (antigen)
Carcinoembryonic antigen
Epidermal growth factor receptors
Interleukin 6
Tenascins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunoconjugates binding to; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**labeled**; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (light chain, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (monoclonal, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Lymphoma**
(non-Hodgkin's, diagnosis and treatment of; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (single chain, anti-CD74; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)
IT 27928-00-3 66106-91-0
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**labeled antibody**; anti-CD74 immunoconjugates and their therapeutic and diagnostic uses)

L96 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2004:2624 HCAPLUS
DOCUMENT NUMBER: 140:55677
TITLE: Anti-**tenascin antibody** fragments and minibodies for treatment of lymphoma
INVENTOR(S): Bigner, Darrell; Zalutsky, Michael; Kuan, Chien-Tsun
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004000216 A2 20031231 WO 2003-US19268 20030619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2002-390864P P 20020621
ED Entered STN: 02 Jan 2004
AB The authors disclose treatment of lymphoma comprising administering antibody fragments, minibodies, or mixts. thereof that bind to tenascin in a therapeutically effective amount Preferably the antibody fragment is a fragment of monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody fragment is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as 131I.
IC ICM A61K
CC 8-7 (Radiation Biochemistry)
Section cross-reference(s): 1, 14, 15
ST **tenascin antibody** fragment minibody lymphoma radioimmunotherpy
IT Antitumor agents
(anti-**tenascin antibody** fragments and minibodies)
IT **Hodgkin's disease**
(anti-**tenascin antibody** fragments and minibodies for treatment of)
IT Aves
Human
Mammalia
(anti-**tenascin antibody** fragments and minibodies for treatment of lymphoma)
IT **Antibodies** and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fragments, F(ab')2, **labeled**; to **tenascin** for treatment of lymphoma)
IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monoclonal, **81C6**; treatment of lymphoma with fragments and minibodies generated from)
IT **Lymphoma**
(non-Hodgkin's; anti-**tenascin antibody** fragments and minibodies for treatment of)
IT **Antibodies** and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(single chain, **labeled**; to **tenascin** for treatment of lymphoma)
IT Drug resistance
(treatment of lymphoma with anti-**tenascin antibody** fragments and minibodies in relation to)
IT Radionuclides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of lymphoma with anti-**tenascin antibody** fragments and minibodies **labeled** with)
IT **Tenascins**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of lymphoma with **antibody** fragments and minibodies to)
IT **Immunoradiotherapy**

(with **labeled** anti-**tenascin antibody** fragments and minibodies)
IT 10043-66-0D, Iodine-131, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
10098-91-6D, Yttrium-90, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
14378-26-8D, Rhenium-188, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
14913-49-6D, Bismuth-212, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
14998-63-1D, Rhenium-186, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
15092-94-1D, Lead-212, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
15755-39-2D, Astatine-211, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
15757-86-5D, Copper-67, anti-**tenascin antibody** fragments and minibodies **labeled** with, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for treatment of lymphoma)
IT 50-18-0, Cyclophosphamide 53-03-2, Prednisone 57-22-7, Vincristine 23214-92-8, Doxorubicin 174722-31-7, Rituximab
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of lymphoma with anti-**tenascin antibody** fragments and minibodies in relation to resistance to)

L96 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8
ACCESSION NUMBER: 2003:719519 HCAPLUS
DOCUMENT NUMBER: 139:259963
TITLE: Anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers
INVENTOR(S): Hansen, Hans; Leung, Shui-on; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074567	A2	20030912	WO 2003-GB890	20030303
WO 2003074567	A3	20031231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478012	AA	20030912	CA 2003-2478012	20030303
EP 1483294	A2	20041208	EP 2003-743421	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-360259P P 20020301
WO 2003-GB890 W 20030303

ED Entered STN: 14 Sep 2003
AB The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
IC ICM C07K016-28
ICS A61K039-395; A61P035-02; G01N033-574
CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 3, 9, 63
ST CD74 **antibody** conjugate vaccine immune autoimmune disease infection cancer
IT Interleukins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(21; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(B cell lineage; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Leukemia
Lymphoma
(B-cell; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Disease, animal
(B-lymphocyte, malignancy; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD126; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD33; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD37; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Glycoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD40-L (antigen CD40 ligand); anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD52; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Genetic vectors
(GS; anti-CD74 **antibodies** and conjugates for diagnosis and

treatment of immune and autoimmune diseases, infections and cancers)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-DR; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HM1.24; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(I-A; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ICAM-1 (intercellular adhesion mol. 1); anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE type II; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IgG1; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG2a; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG3; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgG4; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IgG; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCP (membrane cofactor protein); anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune

diseases, infections and cancers)
IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class I; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC (major histocompatibility complex), class II; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Imaging
(NMR; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Animal cell line
(Raji; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSEA-1 (stage-specific embryonic antigen 1); anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Leukemia
Lymphoma
(T-cell; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Disease, animal
(T-lymphocyte, malignancy; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Leukemia
(acute lymphocytic; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Diagnosis
(agents, immunoconjugates; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Animal tissue culture
Antigen-presenting cell
Antiserums
Antitumor agents
Autoimmune disease
Blood
Body fluid
Capra
Carcinoma
Cytotoxic agents
DNA sequences
Epitopes
Eubacteria
Genetic vectors
Hodgkin's disease

Human
Immunomodulators
Immunotherapy
Infection
Labels
Leukemia
Lymphocyte
Lymphoma
Melanoma
Molecular cloning
Multiple myeloma
Mus
Neoplasm
Pathogen
Positron-emission tomography
Protein sequences
Rodentia
Sarcoma
Transplant rejection
Tumor markers
Vaccines
Yeast
(anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
Antibodies and Immunoglobulins
Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Antisense oligonucleotides
CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD30 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD5 (antigen)
CD8 (antigen)
CD80 (antigen)
CD80 (antigen)
Cytokines
Enzymes, biological studies
Hemopoietins
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Invariant chain (class II antigen)
Invariant chain (class II antigen)
Lymphotoxin
Radionuclides, biological studies

Stem cell factor
Tenascins
Toxins
cDNA
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bispecific; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Diagnosis
(cancer; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Intestine, neoplasm
Lung, neoplasm
Stomach, neoplasm
(carcinoma; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Drug delivery systems
(carriers; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Multiple myeloma
(cell; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Leukemia
(chronic lymphocytic; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT T cell (lymphocyte)
(disease, malignancy; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Immunity
(disorder; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion products; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Liposomes
(gas-filled; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Carcinoma
(gastric; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Transplant and Transplantation
(graft-vs.-host reaction; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Drug delivery systems
Drugs
(immunoconjugates; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Diagnosis
(immunodiagnosis; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Scintigraphy
(immunoscintigraphy, radio; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Drug delivery systems
(immunotoxins; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Parasite
(infection; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Biomarkers (biological responses)
(inflammatory cell; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Drug delivery systems
(injections, i.m.; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Drug delivery systems
(injections, i.v.; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Biological transport
(internalization; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Carcinoma
(intestinal; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections

and cancers)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT B cell (lymphocyte)
(lineage antigen; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Drug delivery systems
(liposomes, gas-filled; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Animal cell
(mammalian; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Inflammation
(marker; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multi-specific; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT **Lymphoma**
(non-Hodgkin's; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Genetic vectors
(pdHL2; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Carcinoma
(pulmonary; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Kidney, neoplasm
(renal cell carcinoma; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Carcinoma
(renal cell; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Acoustic devices
(scanning; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)
IT Mutagenesis

(site-directed, substitution; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Neoplasm
(solid; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Vaccines
(tumor; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Complement receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 2; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Antitumor agents
(vaccines; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Interleukin 2 receptors
Interleukin 2 receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α chain; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT 600427-07-4P 600427-08-5P 600427-09-6P 600427-10-9P 600427-11-0P 600427-12-1P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT 313064-51-6P 600164-70-3P 600164-71-4P 600164-72-5P 600164-73-6P 600164-74-7P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT 9014-42-0, Thrombopoietin 11096-26-7, Erythropoietin 62683-29-8, Colony-stimulating factor 83869-56-1, GM-CSF 143011-72-7, G-CSF
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT 600427-01-8P 600427-02-9P 600427-03-0P 600427-04-1P 600427-05-2P
600427-06-3P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

IT 600427-31-4 600427-32-5 600427-33-6 600427-34-7 600427-35-8
600427-36-9 600427-37-0 600427-38-1 600427-39-2 600427-40-5
600427-41-6 600427-42-7 600427-43-8 600427-44-9 600427-45-0
600427-46-1
RL: PRP (Properties)
(unclaimed sequence; anti-CD74 **antibodies** and conjugates for diagnosis and treatment of immune and autoimmune diseases, infections and cancers)

L96 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 9
ACCESSION NUMBER: 2003:656808 HCAPLUS
DOCUMENT NUMBER: 139:196278
TITLE: Anti-CD20 **antibodies** and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases
INVENTOR(S): Hansen, Hans; Qu, Zhengxing; Goldenberg, David M.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003068821	A2	20030821	WO 2003-GB665		20030214
WO 2003068821	A3	20050120			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2476166	AA	20030821	CA 2003-2476166		20030214
US 2003219433	A1	20031127	US 2003-366709		20030214
PRIORITY APPLN. INFO.:			US 2002-356132P	P	20020214
			US 2002-416232P	P	20021007
			WO 2003-GB665	W	20030214

ED Entered STN: 22 Aug 2003
AB The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.
IC ICM C07K016-28
ICS A61K039-395; C12N015-13; C12N005-10; G01N033-53

CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 3, 8, 9, 63
ST humanized chimeric monoclonal **antibody** human CD20 B cell disorder
IT Interleukins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(21; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Leukemia
Lymphoma
(B-cell; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Disease, animal
(B-lymphocyte; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD126; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD33; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD37; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Glycoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD40-L (antigen CD40 ligand); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD52; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Genetic vectors
(GS; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-DR; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(HM1.24; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ICAM-1 (intercellular adhesion mol. 1); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ia (H-2 I-region-associated); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE type II; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IgG1; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IgG; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MCP (membrane cofactor protein); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PAP (pokeweed antiviral protein); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Growth factors, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S1 factor; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(SSEA-1 (stage-specific embryonic antigen 1); humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Diagnosis
(agents; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Sulfonic acids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkanesulfonic, salts; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Cytotoxic agents
(antimetabolites; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bispecific; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Abrins
Ricins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Imaging agents
(contrast; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria, conjugates; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxins, Pseudomonas; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enterotoxin A, Staphylococcal; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(enterotoxins, staphylococcal A; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exotoxins, Pseudomonas; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion products; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Alkylating agents, biological
Angiogenesis inhibitors
Antibiotics
Autoimmune disease
B cell (lymphocyte)
Biomarkers (biological responses)
Canis familiaris
Color formers
Cytotoxic agents
DNA sequences
Domestic animal
Drug delivery systems
Drugs
Dyes
Epitopes
Felis catus
Genetic vectors
Human
Imaging agents
Immunomodulators
Immunotherapy
Labels
Lymphocyte
Lymphoma
Mammalia
Molecular cloning
Multiple myeloma
Mus
Myasthenia gravis
Protein sequences
Pseudomonas

Rodentia
Transplant rejection
cDNA sequences
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Abrins
Alkaloids, biological studies
Anthracyclines
Antisense oligonucleotides
CD14 (antigen)
CD19 (antigen)
CD20 (antigen)
CD22 (antigen)
CD38 (antigen)
CD4 (antigen)
CD40 (antigen)
CD5 (antigen)
CD8 (antigen)
CD80 (antigen)
CD80 (antigen)
Cytokines
Enzymes, biological studies
Fusion proteins (chimeric proteins)
Hemopoietins
Hormones, animal, biological studies
Interferons
Interleukin 1
Interleukin 10
Interleukin 12
Interleukin 18
Interleukin 2
Interleukin 3
Interleukin 6
Interleukins
Invariant chain (class II antigen)
Lymphotoxin
Oligonucleotides
Radionuclides, biological studies
Ricins
Stem cell factor
Tenascins
Toxins
Transforming proteins
Tumor necrosis factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; humanized or chimeric monoclonal anti-CD20

antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Purpura (disease)
(idiopathic thrombocytopenic, chronic; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Drug delivery systems
(immunoconjugates; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Diagnosis
(immunodiagnosis; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Drug delivery systems
(immunotoxins; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Apoptosis
Mitosis
(inhibitors; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Paramagnetic materials
(ion; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Animal cell
(mammalian; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Lymphoma**
(non-Hodgkin's; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Metals, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-radioactive; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Gene, animal
Gene, microbial
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oncogene; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Genetic vectors
(pdHL2; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Chemicals
(photoactive; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Rheumatoid arthritis
(progressive; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporin; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(saporins, conjugates; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Corticosteroids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppressant; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Complement receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 2; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Alkaloids, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α chain; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(β; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(COX-2 inhibitors; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 581975-93-1DP, humanized derivs. 581975-95-3DP, humanized derivs.
581976-04-7DP, chimeric conjugates with anti-CD20 **antibody** A20
581976-05-8DP, chimeric conjugates with anti-CD20 **antibody** A20
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 192433-87-7P 192705-48-9P 444104-00-1P 556112-97-1P 556112-98-2P
556112-99-3P 556113-00-9P 581804-64-0P 581804-65-1P 581804-66-2P
581804-67-3P 581804-68-4P 581804-69-5P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 55-86-7, Nitrogen mustard 57-13-6D, Urea, substituted derivs.
59-30-3D, Folic acid, analogs 60-34-4D, Methylhydrazine, derivs.
120-73-0D, Purine, analogs 151-56-4D, Ethylenimine, derivs. 289-95-2D, Pyrimidine, analogs 1605-68-1D, Taxane, analogs 4375-07-9D, Epipodophyllotoxin, derivs. 7439-89-6, Iron, biological studies
7439-96-5, Manganese, biological studies 7440-06-4D, Platinum, coordination complexes 7440-54-2, Gadolinium, biological studies
7689-03-4D, Camptothecin, analogs 9001-99-4, Ribonuclease 9003-98-9, DNase I 9014-42-0, Thrombopoietin 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11096-26-7, Erythropoietin 13010-20-3D, Nitrosourea, derivs. 13981-22-1, Nitrogen-13, biological studies 13981-56-1, Fluorine-18, biological studies 13982-43-9, Oxygen-15, biological studies 14119-09-6, Gallium-67, biological studies 14158-30-6, Iodine-124, biological studies 14158-31-7, Iodine-125, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14276-53-0, Copper-62, biological studies 14333-33-6, Carbon-11, biological studies 14378-26-8, Rhenium-188, biological studies 14391-73-2, Copper-66, biological studies 14596-37-3, Phosphorus-32, biological studies 14809-53-1, Yttrium-86, biological studies 14913-49-6, Bismuth-212, biological studies 14998-63-1, Rhenium-186, biological studies 15056-34-5D, Triazene, derivs.
15715-08-9, Iodine-123, biological studies 15750-15-9, Indium-111, biological studies 15755-39-2, Astatine-211, biological studies
15757-14-9, Gallium-68, biological studies 15757-86-5, Copper-67, biological studies 15765-38-5, Bromine-76, biological studies
15776-20-2, Bismuth-213, biological studies 23214-92-8D, Doxorubicin, analogs 33069-62-4D, Taxol, analogs 62683-29-8, Colony stimulating

factor 75037-46-6, Gelonin 83869-56-1, GM-CSF 127464-60-2, Vascular endothelial growth factor 143011-72-7, G-CSF 187888-07-9D, Endostatin, analogs 352423-07-5, Placenta growth factor 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 581975-88-4P 581975-89-5DP, chimeric or humanized derivs. 581975-90-8P 581975-91-9DP, chimeric or humanized derivs. 581975-92-0DP, humanized derivs. 581975-94-2DP, humanized derivs. 581975-96-4P 581975-97-5P 581975-98-6P 581975-99-7P 581976-00-3P 581976-01-4P 581976-02-5DP, chimeric conjugates with anti-CD20 **antibody** A20 581976-03-6DP, chimeric conjugates with anti-CD20 **antibody** A20
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT 145882-18-4 581983-33-7 581983-34-8 581983-35-9 581983-36-0 581983-37-1 581983-38-2 581983-39-3 581983-40-6 581983-41-7 581983-42-8 581983-43-9 581983-44-0 581983-45-1 581983-46-2 581983-47-3 581983-48-4 581983-49-5 581983-50-8 581983-51-9 581983-52-0 581983-53-1 581983-54-2
RL: PRP (Properties)
(unclaimed sequence; anti-CD20 **antibodies** and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

L96 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:648412 HCAPLUS
DOCUMENT NUMBER: 141:162344
TITLE: Anthracycline-**antibody** conjugates
INVENTOR(S): Griffiths, Gary L.
PATENT ASSIGNEE(S): Immunomedics, Inc., USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067038	A1	20040812	WO 2004-US1367	20040120
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
US 2004202666	A1	20041014	US 2004-757543	20040115

PRIORITY APPLN. INFO.: US 2003-442125P P 20030124
ED Entered STN: 12 Aug 2004
AB The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety.
IC ICM A61K047-48
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 8, 15
ST anthracycline conjugate **antibody** drug targeting antitumor
IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(4; antitumor anthracycline-**antibody** conjugates)
IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD33; antitumor anthracycline-**antibody** conjugates)
IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD66; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CSAp; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EPG-1; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HER-2/neu; antitumor anthracycline-**antibody** conjugates)
IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE type II; antitumor anthracycline-**antibody** conjugates)
IT **Antibodies** and Immunoglobulins
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(IgG; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MAGE (melanoma antigen-encoding gene); antitumor anthracycline-**antibody** conjugates)
IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC1; antitumor anthracycline-**antibody** conjugates)
IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC2; antitumor anthracycline-**antibody** conjugates)
IT Mucins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MUC3; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NCA90; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NCA95; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Thomas-Friedenreich; antitumor anthracycline-**antibody** conjugates)
IT B cell (lymphocyte)
(**antibodies** against; antitumor anthracycline-**antibody**

conjugates)
IT Antitumor agents
Carcinoma
Chemotherapy
Digestive tract, neoplasm
Hodgkin's disease
Human
Immunomodulators
Immunotherapy
Leukemia
Lymphoma
Melanoma
Molecular cloning
Nervous system, neoplasm
Neuroglia, neoplasm
Radiotherapy
Reproductive tract, neoplasm
Sarcoma
Skin, neoplasm
Surgery
(antitumor anthracycline-**antibody** conjugates)
IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor anthracycline-**antibody** conjugates)
IT Angiogenic factors
CD19 (antigen)
CD22 (antigen)
CD40 (antigen)
CD80 (antigen)
Carcinoembryonic antigen
Epidermal growth factor receptors
Gangliosides
Interleukin 2
Invariant chain (class II antigen)
Tenascins
Tumor necrosis factors
α-Fetoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antitumor anthracycline-**antibody** conjugates)
IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor anthracycline-**antibody** conjugates)
IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor anthracycline-**antibody** conjugates)
IT Interleukins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor anthracycline-**antibody** conjugates)
IT **Antibodies** and Immunoglobulins
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(chimeric, conjugates; antitumor anthracycline-**antibody** conjugates)
IT **Antibodies** and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; antitumor anthracycline-**antibody** conjugates)
IT Anthracyclines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs., conjugates; antitumor anthracycline-**antibody** conjugates)

IT Receptors
Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(folate; antitumor anthracycline-**antibody** conjugates)
IT **Antibodies** and Immunoglobulins
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(humanized, conjugates; antitumor anthracycline-**antibody** conjugates)
IT Drug delivery systems
(immunoconjugates; antitumor anthracycline-**antibody** conjugates)
IT Drug delivery systems
(injections; antitumor anthracycline-**antibody** conjugates)
IT Leukemia
(myelogenous; antitumor anthracycline-**antibody** conjugates)
IT Endocytosis
(receptor-mediated; antitumor anthracycline-**antibody** conjugates)
IT Drug delivery systems
(targeted; antitumor anthracycline-**antibody** conjugates)
IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tumor-specific antigens; antitumor anthracycline-**antibody** conjugates)
IT Complement receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 2; antitumor anthracycline-**antibody** conjugates)
IT Interleukin 2 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α chain; antitumor anthracycline- **antibody** conjugates)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IX; antitumor anthracycline-**antibody** conjugates)
IT 62229-50-9, Egf 127464-60-2, Vascular endothelial growth factor 352423-07-5, Plgf
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antitumor anthracycline-**antibody** conjugates)
IT 20830-81-3D, Daunorubicin, **antibody** conjugates 23214-92-8D, Doxorubicin, **antibody** conjugates 56420-45-2D, Epirubicin, **antibody** conjugates 80790-68-7D, Morpholinodoxorubicin, **antibody** conjugates 88254-07-3D, **antibody** conjugates 175795-76-3D, **antibody** conjugates
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(antitumor anthracycline-**antibody** conjugates)
IT 9014-42-0, Thrombopoietin 11096-26-7, Erythropoietin 83869-56-1, Gmcsf 143011-72-7, Gcsf
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor anthracycline-**antibody** conjugates)
IT 181148-00-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(linker; antitumor anthracycline-**antibody** conjugates)

L96 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:515336 HCAPLUS
DOCUMENT NUMBER: 141:71389
TITLE: Preparation of porphyrin derivatives and their uses in radioimmunotherapy
INVENTOR(S): Boitrel, Bernard Philippe Albert

PATENT ASSIGNEE(S): Centre National De La Recherche Scientifique Cnrs, Fr.; Universite Rennes 1
SOURCE: Fr. Demande, 46 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2849035	A1	20040625	FR 2002-16371	20021220
WO 2004063199	A1	20040729	WO 2003-FR3794	20031218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2002-16371 A 20021220
FR 2003-12341 A 20031022
OTHER SOURCE(S): MARPAT 141:71389
ED Entered STN: 25 Jun 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention claims the compds. I [when A forms with C a chain, X-Y-C6H4-(CH2)n1-C(Z,W)-(CH2)n2-C6H4 (AC); then B forms with D a chain, known as chain data base (BD), of above-mentioned formula, the aforementioned chains AC, and BD, being located independently one of the other, with the top (position α) or with the lower part (position β) plan of porphyrin macrocycle, - or when A forms with D a chain, known as chain AD, of above-mentioned formula, then B forms with C a chain, known as BC chain, of above-mentioned formula, one of the aforesaid chains AD or BC, being located at the top (position α) plan of porphyrin macrocycle, while other chain AD or BC, is located or at the lower part (position β) plan of the porphyrin macrocycle; when X = NH, O, CO, CH2 then Y = CO, CH2, NH, O, resp.; n1, n2 = 1, 2, 3; Z = CN, NO2, CO2-, CH2NR1R2, SO3R3, SO2R3; R1, R2 = H, (un)branched alkyl, C1-8-cycloalkyl, aryl, alkylaryl, antibody; R3 = H, Na, K, NR4R5; R4, R5 = (un)branched alkyl, C1-8-cycloalkyl, 4-nitroaryl; W = CO2-, CO2R6; R6 = H, (un)branched alkyl, C1-8-cycloalkyl, aryl, alc., o-, m-, p-nitrophenol; ZW = Meldrums acid; EF, GH = CH:CH, CH2CH2]. L' of the invention also relates to the complexes between these compds. and of the radioelements, as well as pharmaceutical compns. containing these complexes. Thus, malonate derivative α,α,α,α-I [AB = CD = -2-[NHCOC6H4CH2-3-C(CO2Et)2-3'-CH2C6H4CONH]-2'-; EF = GH = CH:CH] was prepared from α,α,α,α-mesotetrakis(2-aminophenyl)porphyrin via N-acylation with 3-(ClCH2)C6H4COCl, followed by alkylation of CH2(CO2Et)2 by the resulting benzamide.

IC ICM C07D487-22
ICS A61K051-00; A61K049-00; A61K031-409; A61P035-00; C07D207-44; C07D207-323; C07D257-00; A61K103-40; A61K103-00
CC 26-7 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 29, 63, 78

IT **Immunoradiotherapy**
(agents for; preparation of porphyrin derivs. and their uses in radioimmunotherapy)

IT **Lymphoma**
(non-Hodgkin's, radioimaging agents for; preparation of porphyrin derivs. and their uses in radioimmunotherapy)

IT CD20 (antigen)
CD22 (antigen)
Carcinoembryonic antigen
Tenascins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathologies related to, radioimaging agents for; preparation of porphyrin derivs. and their uses in radioimmunotherapy)

IT **Lymphoma**
Neoplasm
(radioimaging agents for; preparation of porphyrin derivs. and their uses in radioimmunotherapy)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L96 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:435061 HCAPLUS
DOCUMENT NUMBER: 139:21033
TITLE: Vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents
INVENTOR(S): Goshorn, Stephen Charles; Graves, Scott Stoll; Schultz, Joanne Elaine; Lin, Yukang; Sanderson, James Allen; Reno, John M.; Dearstyne, Erica A.
PATENT ASSIGNEE(S): NeoRx Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 13,173.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003103948	A1	20030605	US 2002-150762	20020517
US 2003095977	A1	20030522	US 2001-13173	20011207
US 2003143233	A1	20030731	US 2002-244821	20020916
WO 2003050260	A2	20030619	WO 2002-US39429	20021206
WO 2003050260	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1499630	A2	20050126	EP 2002-790070	20021206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 1999-137900P P 19990607
US 1999-168976P P 19991203

US 2000-589870	A2	20000605
US 2001-13173	A2	20011207
US 2002-150762	A2	20020517
US 2002-244821	A	20020916
WO 2002-US39429	W	20021206

ED Entered STN: 06 Jun 2003

AB The present invention provides vectors for expressing Streptomyces avidinii genomic streptavidin (SA) fusion cassettes. A genomic streptavidin expressed gene fusion is expressed as a soluble protein into the periplasmic space of bacteria and undergoes spontaneous folding. Such expression offers the advantage that the periplasm is a low biotin environment and one need not purify and refold the protein under harsh denaturing conditions that may prove fatal to the polypeptide encoded by a heterologous nucleic acid mol. fused to the genomic streptavidin nucleic acid mol. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and streptavidin (scFvSA) are provided as are vectors encoding the same. The single chain antibodies are directed to cell surface antigens or cell-associated stromal or matrix proteins such as CD20, CD45, CD22, CD52, CD56, CD57, EGP40, NCAM, CEA, TAG-72, mucins (MUC1-7), 13HCG, EGF receptor, IL-2 receptor, her2/neu, Lewis Y, GD2, GM2, tenascin, sialylated tenascin, somatostatin, activated tumor stromal antigen or neoangiogenic antigens. Also provided, are methods of using the fusion proteins of the present invention, in the absence and presence of a radiation-sensitizing agent, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.

IC ICM A61K048-00
ICS C07H021-04; C12P021-04; C12N001-21; C12N005-06; C07K014-435

NCL 424093210; 435069700; 435320100; 435325000; 536023500; 530350000; 435252300

CC 15-3 (Immunochemistry)
Section cross-reference(s): 3, 9, 63

ST streptavidin **antibody** fusion protein diagnosis cell tumor targeting

IT Gene, animal
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(13HCG; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(17-1A, EGP40; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(B-cell diffuse, large cell; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(B-cell, high-grade; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(B-cell, marginal zone; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(B9E9; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(Burkitt's; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CC49; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD52; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT CD antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD57; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Gene, animal
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ERBB2; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Promoter (genetic element)
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Lac, constitutive, in vector; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Blood-group substances
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Le, Ley, (Lewis Y); vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Gene, animal
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MUC1-7; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Mucins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1-7; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Cell adhesion molecules
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-CAM; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Proteins

RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(SU (surface); vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(T-cell, adult, HTLY-1-associated; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(T-cell, peripheral; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(T-cell, stages Ib through IV cutaneous; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(TAG-72 (tumor-associated glycoprotein 72); vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Lymphoproliferative disorders
(Waldenstrom's macroglobulinemia; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(activated tumor stromal antigen; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(acute lymphocytic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(acute myelogenous; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Carcinoma
(adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(anti-CD25, or fragments; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Mus
Rattus
Rodentia
(**antibody** from; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Radionuclides, biological studies

RL: ARG (Analytical reagent use); DGN (Diagnostic use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biotinylated, compound containing; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Diagnosis
(cancer; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Appendix
Esophagus, neoplasm
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Stomach, neoplasm
(carcinoma or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Ovary, neoplasm
Salivary gland, neoplasm
(carcinoma, or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Receptors
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell surface protein; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Insecta
(cell, expression host; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Neoplasm
(cell, targeting; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(chronic B-lymphocytic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(chronic lymphocytic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(chronic myelocytic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Genetic element
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cloning sites, in vector; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Intestine, neoplasm
(colon, carcinoma or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Biomarkers (biological responses)
(diagnostic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Salivary gland
(duct, carcinoma, or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Uterus, neoplasm
(endometrium, carcinoma or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Escherichia coli
Eubacteria
Plant cell
(expression host; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Gene, animal
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(for **antibody**; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Gene, microbial
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(for streptavidin, from Streptomyces avidinii; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Radiosensitizers, biological
(for tumor cell targeting; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments, single chain Fv; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Signal peptides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(from Streptomyces avidinii, vector encoding; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Leukemia
(hairy-cell; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heavy chain, single, variable; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)
IT Neoplasm
(hematol.; vectors expressing soluble form of single chain

antibody and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Gene, microbial
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lac, promoter from; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Genetic element
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(leader sequence, bacterial, in vector; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Antibodies** and Immunoglobulins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(light chain, single, variable; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Peptides, biological studies
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(linker, in fusion protein; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(lymphoblastic, precursor B-lymphoblastic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(lymphoplasmacytoid; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Animal cell
(mammalian, expression host; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Proteins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix, cell-associated; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Proteins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane, cell surface; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Diagnosis
(mol., tumor; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens

RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoangiogenic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(nodular; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(non-Hodgkin's, mantle cell; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(non-Hodgkin's; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Carcinoma
(ovarian, or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Organelle
(periplasm, of E. coli, scFvSA expressed into; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(prolymphocytic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Carcinoma
(rectal, or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Intestine, neoplasm
(rectum, carcinoma, or adenocarcinoma; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Genetic element
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(regulatory, from Streptomyces avidinii, in vector; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antibiotic resistance
(selection marker conferring; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(single chain; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(small lymphocytic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Lymphoma**
(splenic marginal zone; vectors expressing soluble form of single chain

antibody and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Leukemia
(stem cell, precursor B-lymphoblastic; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Streptomyces avidinii
(streptavidin from; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Proteins
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stromal, cell-associated; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT **Radiotherapy**
(targeted; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antigens
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Antitumor agents
Carcinoma
DNA sequences
Drug delivery systems
Genetic vectors
Hodgkin's disease
Human
Immunotherapy
Linking agents
Melanoma
Molecular cloning
Multiple myeloma
Neuroglia, neoplasm
Protein sequences
Tumor markers
cDNA sequences
(vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT Angiogenic factors
CD20 (antigen)
CD22 (antigen)

CD45 (antigen)
Carcinoembryonic antigen
Epidermal growth factor receptors
Interleukin 2 receptors
Tenascins
neu (receptor)
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 9002-61-3, Human chorionic gonadotropin
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(13HCG; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 51-21-8, 5-Fluorouracil
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-Fluorouracil, as sensitizing agent; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 2543-43-3
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, Gly-Ser linker; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 538410-22-9DP, subfragments are claimed
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 538410-24-1DP, subfragments are claimed 538410-27-4DP, subfragments are claimed
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 58-85-5, Biotin
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biotin; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 9013-20-1P, Streptavidin
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 95058-81-4, Gemcitabine
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gemcitabine, as sensitizing agent; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 139816-71-0 140528-95-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 538410-21-8 538410-23-0 538410-25-2 538410-26-3
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(nucleotide sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 33069-62-4, Paclitaxel
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(paclitaxel, as as sensitizing agent; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 538454-44-3 538454-48-7 538454-50-1 538454-51-2 538454-52-3
538454-53-4 538454-54-5 538454-55-6 538454-56-7 538454-57-8
538454-58-9 538454-59-0 538454-60-3 538454-61-4 538454-62-5
538454-63-6 538454-64-7 538454-65-8 538454-66-9 538454-67-0
538454-69-2 538454-70-5 538454-71-6 538454-72-7 538454-73-8
538454-74-9 538454-75-0 538454-76-1 538454-77-2 538454-78-3
538454-79-4 538454-80-7 538454-81-8 538454-83-0 538454-85-2
538454-86-3 538454-87-4 538454-88-5 538454-89-6 538454-90-9
538454-91-0 538454-92-1 538454-93-2 538454-94-3 538454-95-4
538454-96-5 538454-97-6 538454-98-7 538454-99-8 538455-00-4
538455-01-5 538455-03-7 538455-04-8 538455-05-9 538455-06-0
538455-07-1 538455-08-2 538455-09-3 538455-10-6 538455-11-7
538455-12-8 538455-13-9 538455-14-0 538455-15-1 538455-16-2
538455-17-3 538455-18-4 538455-19-5 538455-20-8 538455-21-9
538455-23-1 538455-24-2
RL: PRP (Properties)
(unclaimed nucleotide sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 538454-47-6 538454-49-8
RL: PRP (Properties)
(unclaimed protein sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 122024-47-9 149298-31-7 149322-31-6 313058-85-4 313058-86-5
313058-87-6
RL: PRP (Properties)
(unclaimed sequence; vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

IT 19600-01-2, GM2 51110-01-1, Somatostatin 65988-71-8, GD2
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vectors expressing soluble form of single chain **antibody** and streptavidin (scFvSA) fusions and uses thereof as diagnostic markers or as cell specific targeting agents)

L96 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:396269 HCAPLUS
DOCUMENT NUMBER: 138:400405
TITLE: Streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting
INVENTOR(S): Goshorn, Stephen Charles; Graves, Scott Stoll; Schultz, Joanne Elaine; Lin, Yukang; Sanderson, James Allen; Reno, John M.
PATENT ASSIGNEE(S): Neorx Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U.S. Ser. No. 589,870
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003095977	A1	20030522	US 2001-13173	20011207
US 2003103948	A1	20030605	US 2002-150762	20020517
US 2003143233	A1	20030731	US 2002-244821	20020916
WO 2003050260	A2	20030619	WO 2002-US39429	20021206
WO 2003050260	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1499630	A2	20050126	EP 2002-790070	20021206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.:		
US 1999-137900P	P	19990607
US 1999-168976P	P	19991203
US 2000-589870	A2	20000605
US 2001-13173	A2	20011207
US 2002-150762	A2	20020517
US 2002-244821	A	20020916
WO 2002-US39429	W	20021206

ED Entered STN: 23 May 2003
AB The present invention provides vectors for expressing genomic streptavidin fusion cassettes and fusion protein produced from the vectors. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided are methods of using the fusion proteins of the present invention, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents. The single chain antibodies are directed to cell surface antigens or cell-associated stromal or matrix protein such as CD20, CD45, CD22, CD52, CD56, CD57, EGP40, NCAM, CEA, TAG-72, mucins (MUC1-7), 13HCG, EGF receptor, IL-2 receptor, her2/neu, Lewis Y, GD2, GM2, tenascin, sialylated tenascin, somatostatin, activated tumor stromal antigen or neoangiogenic antigens.
IC ICM A61K039-00
ICS C07H021-04; C12P021-02; C12N005-06; C12P021-04
NCL 424185100; 435069700; 435320100; 435325000; 530350000; 536023500
CC 15-3 (Immunochemistry)

Section cross-reference(s): 3, 9, 63
ST streptavidin **antibody** fusion protein diagnosis cell tumor targeting
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(17-1A; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(B-cell diffuse, large cell; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(B-cell, chronic lymphocytic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(B-cell, high grade; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(B-cell, marginal zone; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(Burkitt's; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD52; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT CD antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CD57; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Gene, animal
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ERBB2; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Blood-group substances
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ley; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC1; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC2; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC3; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC4; streptavidin-**antibody** fusion proteins for diagnosis

and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC5; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC6; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Mucins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MUC7; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Cell adhesion molecules
Cell adhesion molecules
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-CAM; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SU (surface); streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(T-cell; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TAG-72 (tumor-associated glycoprotein 72); streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Lymphoproliferative disorders
(Waldenstrom's macroglobulinemia; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Leukemia
(acute lymphocytic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Leukemia
(acute myelogenous; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Appendix
Salivary gland, neoplasm
(adenocarcinoma and carcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
Esophagus, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Stomach, neoplasm
(adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Diagnosis
Diagnosis
(cancer; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Esophagus, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Stomach, neoplasm
(carcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Insecta
(cell; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Leukemia
(chronic lymphocytic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Leukemia
(chronic myelocytic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(colon adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Intestine, neoplasm
(colon, adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Intestine, neoplasm
(colon, carcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(colon; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Biomarkers (biological responses)
(diagnostic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Salivary gland
(duct, adenocarcinoma and carcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(endometrial; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Uterus, neoplasm
(endometrium, adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Uterus, neoplasm
(endometrium, carcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(esophageal adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(esophageal; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Gene, animal
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(for **antibody**; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Gene, microbial
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(for streptavidin; streptavidin-**antibody** fusion proteins for

diagnosis and specific cell targeting)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fusion products; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(gastric adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(gastric; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Leukemia
(hairy-cell; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Neoplasm
(hematol.; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(hepatocellular; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Liver, neoplasm
(hepatoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Drug delivery systems
(immunoconjugates; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Diagnosis
(immunodiagnosis; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Animal cell
(insect; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Gene, microbial
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lac, promoter; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leader sequence; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Antibodies** and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT **Lymphoma**
(lymphoblastic, precursor B-; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Leukemia
(lymphocytic, precursor B; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Leukemia
(lymphocytic, pro-; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT **Lymphoma**
(lymphoplasmacytoid; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Animal cell
(mammalian; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(mammary adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(mammary; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Angiogenic factors
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neo-; antigen; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoangiogenic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT **Lymphoma**
(nodular; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT **Lymphoma**
(non-Hodgkin's, mantle cell; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT **Lymphoma**
(non-Hodgkin's; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(ovarian adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(ovarian; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(pancreatic adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(pancreatic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma

(prostatic adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(prostatic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(pulmonary adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(pulmonary; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(rectal adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Carcinoma
(rectal; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Intestine, neoplasm
(rectum, adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Intestine, neoplasm
(rectum, carcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulatory; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(signal sequence; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(small lymphocytic; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Lymphoma**
(splenic marginal zone; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT Antibiotic resistance
Antitumor agents
Carcinoma
DNA sequences
Drug delivery systems
Drug delivery systems
Eubacteria
Genetic vectors
Hodgkin's disease
Human
Immunotherapy
Linking agents
Melanoma
Molecular cloning
Multiple myeloma
Mus
Neuroglia, neoplasm
Plant cell
Protein sequences
Rodentia
Streptomyces avidinii
(streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)
IT **Antibodies** and Immunoglobulins
Fusion proteins (chimeric proteins)

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Peptides, biological studies
Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT CD20 (antigen)
CD22 (antigen)
CD45 (antigen)
Carcinoembryonic antigen
Epidermal growth factor receptors
Interleukin 2 receptors
Mucins
Tenascins
neu (receptor)
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stromal; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT **Radiotherapy**
(targeted; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Neoplasm
(targeting; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Antigens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-associated; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT Carcinoma
(uterine endometrial adenocarcinoma; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT 530171-22-3P 530171-23-4P 530171-24-5P 530171-25-6P 530171-26-7P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT 9013-20-1P, Streptavidin
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT 2543-43-3 122024-47-9 149298-31-7 149322-31-6 313058-85-4 313058-86-5 313058-87-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)
(linker; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT 530171-06-3P 530171-07-4P 530171-08-5P 530171-09-6P 530171-10-9P
530171-11-0P 530171-12-1P 530171-13-2P 530171-14-3P 530171-15-4P
530171-16-5P 530171-17-6P 530171-18-7P 530171-19-8P 530171-20-1P
530171-21-2P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT 58-85-5, Biotin 9002-61-3, Human chorionic gonadotropin 19600-01-2, GM2 51110-01-1, Somatostatin 65988-71-8, GD2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

IT 530171-91-6 530171-92-7 530171-93-8 530171-94-9 530171-95-0
530171-96-1 530171-97-2 530171-98-3 530171-99-4 530172-00-0
530172-01-1 530172-02-2 530172-03-3 530172-04-4 530172-05-5
530172-06-6 530172-07-7 530172-08-8 530172-09-9 530172-10-2
530172-11-3 530172-12-4 530172-13-5 530172-14-6 530172-15-7
530172-16-8 530172-17-9 530172-18-0 530172-19-1 530172-20-4
530172-21-5 530172-22-6 530172-23-7 530172-24-8 530172-25-9
530172-26-0 530172-27-1 530172-28-2 530172-29-3 530172-30-6
530172-31-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; streptavidin-**antibody** fusion proteins for diagnosis and specific cell targeting)

L96 ANSWER 14 OF 21 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2004464623 EMBASE
TITLE: Targeted therapy for malignant gliomas.
AUTHOR: Morokoff A.P.; Novak U.
CORPORATE SOURCE: Dr. A.P. Morokoff, Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Vic., Australia. a_morokoff@hotmail.com
SOURCE: Journal of Clinical Neuroscience, (2004) 11/8 (807-818).
Refs: 176
ISSN: 0967-5868 CODEN: JCNUE6
PUBLISHER IDENT.: S 0967-5868(04)00063-3
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
The identification of markers that are associated with tumour but not normal tissue has allowed the development of highly-specific targeted therapies. Monoclonal antibodies, either alone or linked to radioisotopes or toxins, have provided a powerful tool for research, as well as the basis for promising therapeutic agents with less side effects than standard radiotherapy or chemotherapy. A new class of drugs, the tyrosine kinase inhibitors, which interfere with the function of key molecules in cancer-promoting pathways, have

had a dramatic effect in haematological malignancy and are being trialled in solid tumours, including glioma. Although the problem of achieving specific, high-level delivery of these various agents to tumours in the brain remains a major issue, encouraging early results with some targeted agents support the attractive theoretical principles of this new paradigm. Further work to identify new molecular targets and to develop agents exploiting them, is needed, as well as confirmation of their safety and efficacy by clinical trials.

CONTROLLED TERM: Medical Descriptors:
*drug targeting
*glioma: DT, drug therapy
disease marker
cancer radiotherapy
cancer chemotherapy
nonhodgkin lymphoma: DT, drug therapy
chronic lymphatic leukemia: DT, drug therapy
breast cancer: DT, drug therapy
receptor down regulation
opsonization
dimerization
cell cycle
protein degradation
DNA damage
liver toxicity: SI, side effect
gastrointestinal toxicity: SI, side effect
skin toxicity: SI, side effect
tumor lysis syndrome: SI, side effect
heart arrhythmia: SI, side effect
lung toxicity: SI, side effect
cardiotoxicity: SI, side effect
drug delivery system
drug eruption: SI, side effect
nausea: SI, side effect
chemotherapy induced emesis: SI, side effect
diarrhea: SI, side effect
drug tolerability
drug efficacy
drug safety
human
clinical trial
review
priority journal
Drug Descriptors:
monoclonal antibody: AE, adverse drug reaction
monoclonal antibody: CT, clinical trial
monoclonal antibody: DT, drug therapy
rituximab: AE, adverse drug reaction
rituximab: CT, clinical trial
rituximab: DT, drug therapy
trastuzumab: AE, adverse drug reaction
trastuzumab: CT, clinical trial
trastuzumab: DT, drug therapy
taxane derivative: AE, adverse drug reaction
taxane derivative: CT, clinical trial
taxane derivative: DT, drug therapy
imatinib: AE, adverse drug reaction
imatinib: CT, clinical trial
imatinib: DT, drug therapy
gefitinib: AE, adverse drug reaction
gefitinib: CT, clinical trial
gefitinib: CB, drug combination

gefitinib: DT, drug therapy
erlotinib: AE, adverse drug reaction
erlotinib: CT, clinical trial
erlotinib: CB, drug combination
erlotinib: DT, drug therapy
semaxanib: AE, adverse drug reaction
semaxanib: CT, clinical trial
semaxanib: DT, drug therapy
vatalanib: AE, adverse drug reaction
vatalanib: CT, clinical trial
vatalanib: DT, drug therapy
rapamycin: AE, adverse drug reaction
rapamycin: CT, clinical trial
rapamycin: DT, drug therapy
rapamycin 2,2 bis(hydroxymethyl)propionate: AE, adverse drug reaction
rapamycin 2,2 bis(hydroxymethyl)propionate: CT, clinical trial
rapamycin 2,2 bis(hydroxymethyl)propionate: DT, drug therapy
cilengitide: AE, adverse drug reaction
cilengitide: CT, clinical trial
cilengitide: DT, drug therapy
thalidomide: AE, adverse drug reaction
thalidomide: CT, clinical trial
thalidomide: DT, drug therapy
tipifarnib: AE, adverse drug reaction
tipifarnib: CT, clinical trial
tipifarnib: DT, drug therapy
isis 3521: AE, adverse drug reaction
isis 3521: CT, clinical trial
isis 3521: DT, drug therapy
lonafarnib: AE, adverse drug reaction
lonafarnib: CT, clinical trial
lonafarnib: DT, drug therapy
atrasentan: AE, adverse drug reaction
atrasentan: CT, clinical trial
atrasentan: DT, drug therapy
celecoxib: AE, adverse drug reaction
celecoxib: CT, clinical trial
celecoxib: DT, drug therapy
temozolomide: AE, adverse drug reaction
temozolomide: CT, clinical trial
temozolomide: DT, drug therapy
lomustine: AE, adverse drug reaction
lomustine: CT, clinical trial
lomustine: DT, drug therapy
irinotecan: AE, adverse drug reaction
irinotecan: CT, clinical trial
irinotecan: CB, drug combination
irinotecan: DT, drug therapy
cetuximab: AE, adverse drug reaction
cetuximab: CT, clinical trial
cetuximab: DT, drug therapy
tenascin: AE, adverse drug reaction
tenascin: CT, clinical trial
tenascin: DT, drug therapy
protein tyrosine kinase inhibitor: AE, adverse drug reaction
protein tyrosine kinase inhibitor: CT, clinical trial
protein tyrosine kinase inhibitor: DT, drug therapy
protein tyrosine kinase inhibitor: PO, oral drug

administration
leflunomide: AE, adverse drug reaction
leflunomide: CT, clinical trial
leflunomide: DT, drug therapy
leflunomide: PO, oral drug administration
2,4 dimethyl 5 (2 oxo 1h indol 3 ylmethylene) 3 pyrrolepropionic acid: AE, adverse drug reaction
2,4 dimethyl 5 (2 oxo 1h indol 3 ylmethylene) 3 pyrrolepropionic acid: CT, clinical trial
2,4 dimethyl 5 (2 oxo 1h indol 3 ylmethylene) 3 pyrrolepropionic acid: DT, drug therapy
protein farnesyltransferase inhibitor: AE, adverse drug reaction
protein farnesyltransferase inhibitor: CT, clinical trial
protein farnesyltransferase inhibitor: DT, drug therapy
marimastat: AE, adverse drug reaction
marimastat: CT, clinical trial
marimastat: DT, drug therapy
rapamycin derivative: AE, adverse drug reaction
rapamycin derivative: CT, clinical trial
rapamycin derivative: DT, drug therapy
unindexed drug
emd 555900

CAS REGISTRY NO.: (rituximab) 174722-31-7; (trastuzumab) 180288-69-1; (imatinib) 152459-95-5, 220127-57-1; (gefitinib) 184475-35-2, 184475-55-6, 184475-56-7; (erlotinib) 183319-69-9, 183321-74-6; (semaxanib) 186610-95-7; (vatalanib) 212141-54-3, 212142-18-2; (rapamycin) 53123-88-9; (rapamycin 2,2 bis(hydroxymethyl)propionate) 162635-04-3, 343261-52-9; (cilengitide) 188968-51-6; (thalidomide) 50-35-1; (tipifarnib) 192185-72-1; (isis 3521) 151879-73-1; (lonafarnib) 193275-84-2; (atrasentan) 173864-34-1, 173937-91-2, 195733-43-8; (celecoxib) 169590-42-5; (temozolomide) 85622-93-1; (lomustine) 13010-47-4; (irinotecan) 100286-90-6; (cetuximab) 205923-56-4; (leflunomide) 75706-12-6; (2,4 dimethyl 5 (2 oxo 1h indol 3 ylmethylene) 3 pyrrolepropionic acid) 252916-29-3; (marimastat) 154039-60-8

CHEMICAL NAME: (1) Rituxan; (2) Herceptin; (3) Emd 555900; (4) Erbitux; (5) Gleevec; (6) Iressa; (7) Tarceva; (8) Su 5416; (9) Affinitak; (10) Emd 121974; (11) Cci 779; (12) Abt 627; Su 6668

COMPANY NAME: (1) Idec (United States); (4) Imclone (United States); (5) Novartis (United States); (6) Astra Zeneca (United Kingdom); (7) Genentech (United States); (8) Pfizer (United States); (9) Isis (United States); (10) Merck (Germany); (11) Wyeth (United States); (12) Abbott (United States); British Biotechnology (United Kingdom)

L96 ANSWER 15 OF 21 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2001382514 EMBASE

TITLE: Monoclonal antibody therapy in the treatment of non-hodgkin lymphoma.

AUTHOR: McCune S.L.; Gockerman J.P.; Rizzieri D.A.

CORPORATE SOURCE: Dr. D.A. Rizzieri, Division of Oncology, Duke University Medical Center, Box 3961 North Pavilion, 2400 Pratt St, Durham, NC 27710, United States. rizzi003@mc.duke.edu

SOURCE: Journal of the American Medical Association, (12 Sep 2001) 286/10 (1149-1152).
Refs: 31
ISSN: 0098-7484 CODEN: JAMAAP

COUNTRY: United States
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 006 Internal Medicine
016 Cancer
025 Hematology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
***nonhodgkin lymphoma: DT, drug therapy**
***cancer immunotherapy**
leukemia: DT, drug therapy
ischemic heart disease: PC, prevention
kidney graft rejection: CO, complication
kidney graft rejection: DT, drug therapy
kidney graft rejection: PC, prevention
rheumatoid arthritis: DT, drug therapy
Crohn disease: DT, drug therapy
respiratory tract disease: PC, prevention
breast cancer: DT, drug therapy
treatment indication
antigen antibody reaction
drug mechanism
cancer combination chemotherapy
drug induced disease: SI, side effect
fever: DT, drug therapy
fever: SI, side effect
hypotension: DT, drug therapy
hypotension: SI, side effect
respiratory distress: DT, drug therapy
respiratory distress: SI, side effect
human
clinical trial
phase 3 clinical trial
human cell
short survey
priority journal
Drug Descriptors:
***monoclonal antibody: AE, adverse drug reaction**
***monoclonal antibody: CT, clinical trial**
***monoclonal antibody: CB, drug combination**
***monoclonal antibody: DO, drug dose**
***monoclonal antibody: DT, drug therapy**
***monoclonal antibody: PD, pharmacology**
***rituximab: CT, clinical trial**
***rituximab: CB, drug combination**
***rituximab: DO, drug dose**
***rituximab: DT, drug therapy**
***rituximab: PD, pharmacology**
*alemtuzumab: DT, drug therapy
*alemtuzumab: PD, pharmacology
***immunotoxin: CB, drug combination**
***yttrium 90: CB, drug combination**
*ibritumomab tiuxetan: CB, drug combination
*ibritumomab tiuxetan: DT, drug therapy
***tositumomab: CB, drug combination**
***tositumomab: DT, drug therapy**
***iodine 131: CB, drug combination**
human monoclonal antibody: AE, adverse drug reaction
human monoclonal antibody: CT, clinical trial

human monoclonal antibody: CB, drug combination
human monoclonal antibody: DO, drug dose
human monoclonal antibody: DT, drug therapy
human monoclonal antibody: PD, pharmacology
abciximab: PD, pharmacology
interleukin 2 receptor antibody: DT, drug therapy
interleukin 2 receptor antibody: PD, pharmacology
gemtuzumab ozogamicin: DT, drug therapy
gemtuzumab ozogamicin: PD, pharmacology
OKT 3: DT, drug therapy
OKT 3: PD, pharmacology
palivizumab: PD, pharmacology
infliximab: DT, drug therapy
infliximab: PD, pharmacology
trastuzumab: DT, drug therapy
trastuzumab: PD, pharmacology
antineoplastic agent: CT, clinical trial
antineoplastic agent: CB, drug combination
antineoplastic agent: DT, drug therapy
fludarabine: CT, clinical trial
fludarabine: CB, drug combination
fludarabine: DT, drug therapy
cyclophosphamide: CB, drug combination
cyclophosphamide: DT, drug therapy
doxorubicin: CB, drug combination
doxorubicin: DT, drug therapy
vincristine: CB, drug combination
vincristine: DT, drug therapy
prednisone: CB, drug combination
prednisone: DT, drug therapy
tenascin
tumor necrosis factor alpha
CD52 antigen
alpha interferon: CB, drug combination
alpha interferon: DT, drug therapy
antipyretic agent: DT, drug therapy
steroid: DT, drug therapy
antihistaminic agent: DT, drug therapy
unclassified drug

CAS REGISTRY NO.: (rituximab) 174722-31-7; (yttrium 90) 10098-91-6; (tositumomab) 208921-02-2; (iodine 131) 10043-66-0, 15124-39-7; (abciximab) 143653-53-6; (interleukin 2 receptor antibody) 179045-86-4; (OKT 3) 140608-64-6; (palivizumab) 188039-54-5; (infliximab) 170277-31-3; (trastuzumab) 180288-69-1; (fludarabine) 21679-14-1; (cyclophosphamide) 50-18-0; (doxorubicin) 23214-92-8, 25316-40-9; (vincristine) 57-22-7; (prednisone) 53-03-2

L96 ANSWER 16 OF 21 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 96106033 EMBASE
DOCUMENT NUMBER: 1996106033
TITLE: Radioimmunotherapy: Recent results and future directions.
AUTHOR: Wilder R.B.; DeNardo G.L.; DeNardo S.J.
CORPORATE SOURCE: Molecular Cancer Institute, 1508 Alhambra Blvd,Sacramento, CA 95816, United States
SOURCE: Journal of Clinical Oncology, (1996) 14/4 (1383-1400). ISSN: 0732-183X CODEN: JCONDN
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 016 Cancer
023 Nuclear Medicine

025 Hematology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:

Purpose: To review antibody structure, function, and production; suitable radioisotopes for radioimmunotherapy; challenges facing the field; recent clinical results; toxicity; and future directions. Design: The radioimmunotherapy literature was reviewed, with an emphasis on clinical results and future directions. Results: The highest complete response rates (overall, 50%) have been achieved in patients with B-cell non-Hodgkin's lymphoma. Challenges that currently face radioimmunotherapy include circulating free antigen, binding of antibodies to nonspecific Fc receptors, insufficient tumor penetration, antigenic heterogeneity and insufficient antigen expression, antigenic modulation, and development of human antimouse antibodies. Possible approaches to these challenges, including high-dose radioimmunotherapy and chemotherapy followed by autologous bone marrow transplantation, the use of radionuclides such as yttrium 90 (90Y) and copper 67 (67Cu), and the development of humanized and bifunctional antibodies, are under investigation. Conclusion: Although radioimmunotherapy is a relative new field, substantial progress has been made. Additional research will ultimately resolve many of the challenges that currently face radioimmunotherapy and hopefully lead to the cure of some currently incurable malignancies.

CONTROLLED TERM: Medical Descriptors:
***b cell lymphoma: RT, radiotherapy**
***nonhodgkin lymphoma: RT, radiotherapy**
*solid tumor: RT, radiotherapy
allergic reaction: SI, side effect
autologous bone marrow transplantation
bone marrow suppression: SI, side effect
cardiotoxicity: SI, side effect
clinical trial
diarrhea: SI, side effect
drug half life
dyspnea: SI, side effect
fever: SI, side effect
human
intraarterial drug administration
intraperitoneal drug administration
intratumoral drug administration
intravenous drug administration
liver toxicity: SI, side effect
lung toxicity: SI, side effect
major clinical study
nausea: SI, side effect
phase 1 clinical trial
phase 2 clinical trial
priority journal
pruritus: SI, side effect
radioimmunotherapy
radioisotope decay
radioisotope therapy
review
urticaria: SI, side effect
Drug Descriptors:
***antibody conjugate: AE, adverse drug reaction**
***antibody conjugate: AD, drug administration**
***antibody conjugate: TO, drug toxicity**
***copper 67: PK, pharmacokinetics**
***immunoglobulin g antibody: AD, drug administration**

***immunoglobulin g antibody: AE, adverse drug reaction**
***lymphocyte antibody: CT, clinical trial**
***lymphocyte antibody: AD, drug administration**
*tumor antigen
***yttrium 90: PK, pharmacokinetics**
Fc receptor
alpha interferon
astatine 211: PK, pharmacokinetics
bismuth
carcinoembryonic antigen monoclonal antibody
chimeric antibody
cytotoxin
ferritin antibody: AD, drug administration
ferritin antibody: CT, clinical trial
gamma interferon
ganglioside antibody
immunoglobulin g1
interleukin 2
interleukin 2 receptor antibody: AD, drug administration
interleukin 2 receptor antibody: CT, clinical trial
lutetium
lymphocyte antigen
monoclonal antibody b.72.3
nerve cell adhesion molecule
radioisotope
receptor antibody
rhenium 188: PK, pharmacokinetics
tenascin
tirapazamine
unindexed drug

CAS REGISTRY NO.: (copper 67) 15757-86-5; (yttrium 90) 10098-91-6; (astatine 211) 15755-39-2; (bismuth) 7440-69-9; (gamma interferon) 82115-62-6; (interleukin 2) 85898-30-2; (lutetium) 7439-94-3; (tirapazamine) 27314-97-2
CHEMICAL NAME: Sr 4233

L96 ANSWER 17 OF 21 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-40353 DRUGU T S
TITLE: Phase 1 trial study of 131I-labeled chimeric **81C6** monoclonal antibody for the treatment of patients with non-**Hodgkin lymphoma.**
AUTHOR: Rizzieri D A; Akabani G; Zalutsky M R; Coleman R E; Metzler S D; Bowsher J E; Toaso B; Anderson E; Lagoo A; Clayton S
CORPORATE SOURCE: Univ.Duke
LOCATION: Durham, N.C., USA
SOURCE: Blood (104, No. 3, 642-48, 2004) 4 Fig. 3 Tab. 40 Ref.
CODEN: BLOOAW ISSN: 0006-4971
AVAIL. OF DOC.: Box 3961, Duke University Medical Center, Durham NC 27710, U.S.A. (17 authors). (e-mail: rizzi003@mc.duke.edu).
LANGUAGE: English
DOCUMENT TYPE: Journal

ABSTRACT:

131I-chimeric **81C6** mAb (131I-ch81C6 mAb) infusion resulted in hematologic toxicities and mostly stable disease as the best response in a phase I study of 9 patients with non-**Hodgkin lymphoma** (NHL) who had failed at least 1 prior regimen (e.g., rituximab) and ineligible for other standard curative approaches. 131I-ch81C6 mAb showed a monoexponential clearance of whole-body activity. 131I-ch81C6 mAb showed biexponential

pharmacokinetics in the blood. The patients had chronic lymphocytic leukemia, small lymphocytic **lymphoma**, mucosa-associated lymphoid tissue ***lymphoma*** , or diffuse large cell **lymphoma.** 1 Patient achieved PR and another achieved unconfirmed CR. These findings suggest that 131I-ch81C6 mAb is potentially useful for the treatment of **lymphoma** if methods to protect normal viscera are developed.

SECTION HEADING: T Therapeutics
S Adverse Effects

CLASSIF. CODE: 35 Adverse Reactions
51 Chemotherapy - clinical
64 Clinical Trials
75 Monoclonal Antibodies

CONTROLLED TERM:
[01] **NONHODGKIN** *TR; **LYMPHOMA** *TR; CHRON. *TR; LYMPHOCYTIC *TR; LEUKEMIA *TR; SMALL *TR; LYMPHOID *TR; LARGE-CELL *TR; MARROW-DEPRESSION *AE; LYMPHOPROLIFERATIVE-DISEASE *TR; MARROW-DISEASE *AE; MONOCLONAL *FT; ANTIBODY *FT; IMMUNOGLOBULIN *FT; GLOBULIN *FT; IODINE-LABELED *FT; IN-VIVO *FT; CASES *FT; CYTOSTATIC *FT; PHASE-I *FT; INFUSION *FT; BLOOD *FT; CLEARANCE *FT; HALF-LIFE *FT; PARTIAL *FT; COMPLETE *FT; RESPONSE *FT; PROTEIN *FT; CLIN.TRIAL *FT; INJECTION *FT; PHARMACOKINETICS *FT; TR *FT; AE *FT
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

L96 ANSWER 18 OF 21 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-42319 DRUGU T S
TITLE: Phase I trial with pharmacokinetics, dosimetry, toxicity and response of anti-stromal therapy using 131I labeled chimeric anti-**tenascin** therapy for **lymphoma.**
AUTHOR: Rizzieri D A; Akabani G; Zalutsky M; Coleman R E; Toaso B; Anderson E; Lagoo A; Clayton S; Niedzwiecki D; Moore J O
CORPORATE SOURCE: Univ.Duke; Univ.Emory
LOCATION: Durham, N.C.; Atlanta, Ga., USA
SOURCE: Blood (102, No. 11, Pt. 1, 635a-636a, 2003) 1 Fig. 1 Tab. 1 Ref.
CODEN: BLOOAW ISSN: 0006-4971
AVAIL. OF DOC.: Dept. of Medicine, Duke University Medical Center, Durham, NC, U.S.A. (15 authors).
LANGUAGE: English
DOCUMENT TYPE: Journal

ABSTRACT:

I.v. infusion of 131I-labeled chimeric human-mouse **antibody** to ***tenascin*** was well tolerated with favorable pharmacokinetics (PK) among 9 **lymphoma** patients. **Tenascin** is a stromal protein which is overexpressed in lymphomatous tissue compared to normal visceral sites. (conference abstract: 45th Annual Meeting of the American Society of Hematology, San Diego, California, USA, December 6-9, 2003).

SECTION HEADING: T Therapeutics
S Adverse Effects

CLASSIF. CODE: 8 Pharmacokinetics
35 Adverse Reactions
51 Chemotherapy - clinical
64 Clinical Trials
75 Monoclonal Antibodies

CONTROLLED TERM:
[01] **LYMPHOMA** *TR; NEUTROPENIA *AE; THROMBOCYTOPENIA *AE; RADIOLESION *AE; LYMPHOPROLIFERATIVE-DISEASE *TR; MARROW-DISEASE *AE; CASES *FT; IN-VIVO *FT; PHASE-I *FT; DOSAGE *FT; I.V. *FT; INFUSION *FT; IODINE-LABELED *FT; CHIMERIC *FT; MONOCLONAL *FT; **ANTIBODY** *FT; **RADIOIMMUNOTHERAPY** *FT; HALF-LIFE *FT; CLIN.TRIAL *FT; INJECTION *FT; RADIOTHERAPY *FT; PHARMACOKINETICS *FT; TR *FT; AE *FT
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

L96 ANSWER 19 OF 21 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 10
ACCESSION NUMBER: 2003-19995 BIOTECHDS
TITLE: New multivalent, monospecific binding protein comprising two or more binding sites having affinity for the same single target antigen, where each binding site is associated with scFv fragments, useful for diagnosing or treating tumor; recombinant vector-mediated gene transfer and expression in host cell for use in diagnosis and gene therapy
AUTHOR: ROSSI E; CHANG C K; GOLDENBERG D M
PATENT ASSIGNEE: ROSSI E
PATENT INFO: WO 2003033654 24 Apr 2003
APPLICATION INFO: WO 2002-US32718 15 Oct 2002
PRIORITY INFO: US 2002-404919 22 Aug 2002; US 2001-328835 15 Oct 2001
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2003-513460 [48]
ABSTRACT: DERWENT ABSTRACT:
NOVELTY - A multivalent, monospecific binding protein comprising two or more binding sites having affinity for the same single target antigen, where the binding sites are formed by the association of two or more single chain Fv (scFV) fragments, and each scFV fragment comprises at least two variable domains derived from a humanized or human monoclonal **antibody**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) an expression vector comprising a nucleotide sequence encoding the monospecific diabody, triabody or tetrabody; (2) a host cell comprising the expression vector; (3) diagnosing the presence of a tumor by administering to a subject suspected of having a tumor a detectable amount of the binding protein, and monitoring the subject to detect any binding of the binding protein to tumor; (4) delivering one or more diagnostic and/or therapeutic agents to a tumor by administering the binding protein to the subject; and (5) a kit for therapeutic and/or diagnostic use, comprising the binding protein, and additional reagents, equipments and instructions for use.

BIOTECHNOLOGY - Preferred Protein: The binding protein comprises a monoclonal **antibody** that is specific for a tumor-associated antigen. The tumor-associated antigen is associated with a disease state selected from a carcinoma, a melanoma, a sarcoma, a neuroblastoma, a leukemia, a glioma, a **lymphoma** and a myeloma. The tumor-associated antigen is associated with a type of cancer selected from acute lymphoblastic leukemia, acute myelogenous leukemia, biliary, breast, cervical, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal, endometrial, esophageal, gastric, head and neck, **Hodgkin**'s

lymphoma, lung, medullary thyroid, non-**Hodgkin's lymphoma**, ovarian, pancreatic, prostate and urinary bladder. The tumor-associated antigen is selected from A3, A33, BrE3, CD1, CD1a, CD3, CD5, CD15, CD19, CD20, CD21, CD22, CD23, CD30, CD45, CD74, CD79a, CEA, CSAp, EGFR, EGP-1, EGP-2, Ep-CAM, Ba 733, HER2/neu, KC4, KS-1, KS1-4, Le-Y, MAGE, MUC1, MUC2, MUC3, MUC4, PAM-4, PSA, PSMA, RS5, S100, T101, TAG-72, **tenascin**, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, vascular endothelial growth factor (VEGF), 17-1A, an angiogenesis marker, a cytokine, an immunomodulator, an oncogene marker and an oncogene product. The tumor-associated antigen is carcinoembryonic antigen (CEA). The humanized monoclonal **antibody** is hMN-14. The binding protein further comprises at least one agent selected from a diagnostic agent, a therapeutic agent and their combinations. The diagnostic agent is selected from a conjugate, a radionuclide, a metal, a contrast agent, a tracking agent, a detection agent, and their combinations. The radionuclide is selected from 11C, 13N, 15O, 18F, 32P, 52Mn, 55Co, 62Cu, 64Cu, 67Ga, 68Ga, 72As, 76Br, 82mRb, 83Sr, 89Zr, 90Y, 94mTc, 94Tc, 99mTc, 110In, 111In, 120I, 123I, 124I, 125I, 131I, Gd, 177Lu, 186Re, 188Re, a gamma-emitter, a beta-emitter, a positron emitter, or their combinations. The metal is selected from gadolinium, iron, chromium, copper, cobalt, nickel, dysprosium, rhenium, europium, terbium, holmium, neodymium, and their combinations. The contrast agent is a MRI contrast agent, a CT contrast agent, or an ultrasound contrast agent. The contrast agent is selected from gadolinium ions, lanthanum ions, manganese ions, iron, chromium, copper, cobalt, nickel, dysprosium, rhenium, europium, terbium, holmium, neodymium, another comparable contrast agent, and their combinations. The tracking agent is selected from iodine compounds, barium compounds, gallium compounds, thallium compounds, barium, diatrizoate, ethiodized oil, gallium citrate, iocarmic acid, iocetamic acid, iodamide, iodipamide, iodoxamic acid, iogulamide, iohexol, iopamidol, iopanoic acid, ioprocemic acid, iosefamic acid, ioseric acid, iosulamide meglumine, iosemetic acid, iotasul, iotetric acid, iothalamic acid, iotroxic acid, ioxaglic acid, ioxotrizoic acid, ipodate, meglumine, metrizamide, metrizoate, propyliodone, thallous chloride, and their combinations. The detection agent is selected from an enzyme, a fluorescent compound, a chemiluminescent compound, a bioluminescent compound, a **radioisotope**, and their combinations. The therapeutic agent is selected from a radionuclide, a chemotherapeutic drug, a cytokine, a hormone, a growth factor, a toxin, an immunomodulator, and their combination. The chemotherapeutic drug is selected from vinca alkaloids, anthracyclines, epidophyllotoxins, taxanes, antimetabolites, alkylating agents, antibiotics, Cox-2 inhibitors, antimitotics, antiangiogenic agents, apoptotoic agents, doxorubicin, methotrexate, taxol, CPT-11, camptothecans, nitrogen mustards, alkyl sulfonates, nitrosoureas, triazenes, folk acid analogs, pyrimidine analogs, purine analogs, platinum coordination complexes, hormones, and their combinations. The toxin is selected from ricin, abrin, ribonuclease, DNase I, Staphylococcal enterotoxin A, pokeweed antiviral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin or endotoxin, and their combinations. The immunomodulator is selected from cytokines, stem cell growth factors, lymphotoxins,

hematopoietic factors, colony stimulating factors, interferons, stem cell growth factors, erythropoietin, thrombopoietin, and their combinations. The humanized monoclonal **antibody** is hMN-14. Each scFv comprises the VH and VK regions of hMN-14. Each scFv further comprises an amino acid linker connecting the VH and VK regions of hMN-14. This is a monospecific diabody, where each scFv comprises a sequence of 261 amino acids; a monospecific triabody, where each scFv comprises a sequence of 256 amino acids; or a monospecific tetrabody, where each comprises a sequence of 257 amino acids. Preferred Method:

ACTIVITY - Cytostatic. No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The binding proteins are useful for diagnosing and treating tumors, e.g. carcinoma, a melanoma, a sarcoma, a neuroblastoma, a leukemia, a glioma, a **lymphoma** and a myeloma; or a cancer selected from acute lymphoblastic leukemia, acute myelogenous leukemia, biliary, breast, cervical, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal, endometrial, esophageal, gastric, head and neck, **Hodgkin**'s **lymphoma**, lung, medullary thyroid, non-**Hodgkin**'s **lymphoma**, ovarian, pancreatic, prostate and urinary bladder. When treating a tumor by administering to the subject the binding protein, and/or a therapeutic agent , the therapeutic agent is a chemotherapeutic drug, a toxin, external radiation, brachytherapy radiation agent, a **radiolabeled** protein, an anticancer drug, or an anticancer **antibody** (all claimed).

ADMINISTRATION - Administration is intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, or intrathecal. No dosage is given.

EXAMPLE - No relevant example given. (62 pages)

CLASSIFICATION: THERAPEUTICS, Gene Therapy; GENETIC TECHNIQUES and APPLICATIONS, Gene Expression Techniques and Analysis; DISEASE, Cancer; DISEASE, Blood and Hematopoietic Cells; PHARMACEUTICALS, Antibodies; DIAGNOSTICS, Molecular Diagnostics

CONTROLLED TERMS: RECOMBINANT VECTOR-MEDIATED GENE TRANSFER, EXPRESSION IN HOST CELL, HUMAN MONOCLONAL **ANTIBODY**, APPL. CANCER, CARCINOMA, MELANOMA, SARCOMA, NEUROBLASTOMA, LEUKEMIA, GLIOMA, **LYMPHOMA**, MYELOMA DIAGNOSIS, GENE THERAPY ANIMAL MAMMAL TUMOR DNA SEQUENCE PROTEIN SEQUENCE (22, 33)

L96 ANSWER 20 OF 21 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-642245 [62] WPIDS
CROSS REFERENCE: 1998-230235 [20]; 1999-204989 [17]; 2002-195738 [25]
DOC. NO. NON-CPI: N2004-507914
DOC. NO. CPI: C2004-230849
TITLE: Preparing and purifying radioiodine conjugate useful in **radioimmunotherapy**, involves contacting radioiodinated aminopolycarboxylate-appended peptide that is/ or not conjugated to targeting agent with anion-exchange resin.
DERWENT CLASS: B04 D16 K08 P34 S05
INVENTOR(S): GOVINDAN, S V
PATENT ASSIGNEE(S): (IMMU-N) IMMUNOMEDICS INC
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC

WO 2004071571 A1 20040826 (200462)* EN 37 A61N000-00
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UC
US UZ VC VN YU ZA ZM ZW

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004071571	A1	WO 2004-US3305	20040204

PRIORITY APPLN. INFO: US 2003-359276 20030206
INT. PATENT CLASSIF.:
MAIN: A61N000-00
BASIC ABSTRACT:
WO2004071571 A UPAB: 20041125
NOVELTY - Preparing and purifying (M1) conjugate (I) of radioiodinated aminopolycarboxylate-appended peptide (RAP) and targeting agent, involves (a) providing a solution comprising unbound radioiodine and RAP that is/or not conjugated to a targeting agent, (b) contacting solution with anion-exchange resin, and (c) passing resin and solution together through filter capable of trapping anion-exchange resin particles, where purified (I) is obtained.

ACTIVITY - Cytostatic; Cardiant; Immunosuppressive; Hemostatic; Dermatological; Neuroprotective; Muscular-Gen.; Antiinflammatory; Antirheumatic; Antidiabetic; Hemostatic; Anabolic; Hypertensive; Antiarthritic; Antiulcer; Gastrointestinal-Gen.; Nephrotropic; Hepatotropic; Thyromimetic; Antiallergic; Vasotropic; Antianemic; Nootropic; Antibacterial; Antifungal; Antiviral; Antipyretic; Antirheumatic. No supporting data is given.

MECHANISM OF ACTION - Immunotherapy.

USE - (M1) is useful for preparing and purifying conjugate of radioiodinated aminopolycarboxylate-appended peptide (RAP) and targeting agent. The targeting agent is a monoclonal antibody (MAb) associated with a malignant disease, cardiovascular disease, autoimmune disease (class III autoimmune disease), Alzheimer's disease, or infectious organism. The autoimmune disease is chosen from immune-mediated thrombocytopenias, dermatomyositis, Sjogren's syndrome, multiple sclerosis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous pemphigoid, diabetes mellitus, Henoch-Schonlein purpura, post-streptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangitis ubiterans, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis and fibrosing alveolitis. The immune-mediated thrombocytopenia is acute idiopathic thrombocytopenic purpura or chronic idiopathic thrombocytopenic purpura. The monoclonal antibody is capable of targeting cardiovascular lesions, amyloid deposits, infectious organisms, inflammation, autoimmune diseases, displace or ectopic normal tissues, and liquid cancer or solid cancer. The monoclonal antibody is capable of targeting clots, emboli, atherosclerotic plaques, amyloidosis, bacteria, fungi, rickettsia, viruses, parasites, rheumatoid

arthritis, systemic lupus erythematosis, multiple sclerosis, displaced or ectopic parathyroid tissue, displaced or ectopic endometrium tissue, displaced or ectopic spleen tissue, displaced or ectopic thymus tissue, leukemias, **lymphomas**, carcinomas, sarcomas, gliomas, or melanomas (claimed). (I) is useful in radioimmunodetection and **radioimmunotherapy.**

ADVANTAGE - (M1) enables purification of (I) having enhanced stability in vivo and enhanced retention at tumor sites. (M1) removes both unincorporated radioiodide and unconjugated radioiodinated moiety. (M1) provides greater efficiency of antibody labeling with residualizing iodine labels. (M1) provides higher quality stable radioiodine conjugate preparations having a low aggregate content. (M1) is a simple and safe-handled process occurring in one-pot preparation and purification method. (M1) avoids the cumbersome column method of purification.

Dwg.0/3

FILE SEGMENT: CPI EPI GMPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: B04-G01; B04-G21; B04-N04A; B11-B; B11-C08D2; B14-A01; B14-A02; B14-A04; B14-B02; B14-C03; B14-C04; B14-C06; B14-C09; B14-D01; B14-E10C; B14-F01; B14-F02; B14-F03; B14-F04; B14-F07; B14-G02A; B14-G02D; B14-H01; B14-J01A4; B14-J05; B14-K01; B14-N10; B14-N11; B14-N12; B14-N17; B14-N17C; B14-S01; B14-S04; D05-C11; D05-H11A; K08-X; K09-B; K09-E
EPI: S05-A03X

L96 ANSWER 21 OF 21 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-313738 [29] WPIDS
CROSS REFERENCE: 2003-801085 [75]
DOC. NO. NON-CPI: N2004-249776
DOC. NO. CPI: C2004-119121
TITLE: Treating cancer and metabolic diseases by administering a multi-specific **antibody** having a targeting arm that binds to an antigen and a capture arm that binds to a polymer conjugate comprising a therapeutic agent.
DERWENT CLASS: A96 B04 C06 D16 K08 S03
INVENTOR(S): GOLDENBERG, D M; GRIFFITHS, G L; HANSEN, H J
PATENT ASSIGNEE(S): (IMMU-N) IMMUNOMEDICS INC
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 2004043030	A1	20040304	(200429)*		24	G01N033-574

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2004043030	A1 Provisional	US 2001-308605P	20010731
	CIP of	US 2002-209592	20020731
		US 2003-456580	20030609

PRIORITY APPLN. INFO: US 2001-308605P 20010731; US 2002-209592 20020731; US 2003-456580 20030609
INT. PATENT CLASSIF.:
MAIN: G01N033-574
SECONDARY: A61K039-395
BASIC ABSTRACT:

US2004043030 A UPAB: 20040505
NOVELTY - Diagnosing or treating a disease or disorder, involves administering to a tissue a multi-specific **antibody** (I) or **antibody** fragment, comprising a targeting arm that binds to an antigen on the target site, and a capture arm that binds to a polymer conjugate, and administering to the tissue a polymer conjugate that binds to the capture arm, the polymer conjugate comprising a polymer conjugated to a diagnostic or therapeutic agent.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for photodynamic diagnosis or treatment of a disease or disorder or intravascular or endoscopic method for diagnosing or treating a disease or disorder, involves administering to a tissue a multi-specific **antibody** or **antibody** fragment, comprising a targeting arm that binds to an antigen on the target site, and a capture arm that binds to a polymer conjugate, and administering to the tissue a polymer conjugate that binds to the capture arm, the polymer conjugate comprising a polymer conjugated to a diagnostic or therapeutic agent.

ACTIVITY - Cytostatic; Antiinflammatory; Nootropic; Neuroprotective; Antiatherosclerotic; Vasotropic; Thrombolytic; Immunosuppressive; Nephrotropic; Dermatological; Antirheumatic; Antiarthritic; Hemostatic; Analgesic; Antidiabetic; Antiulcer; Hepatotropic; Thyromimetic; Antiallergic; Antibacterial; Fungicide; Virucide; Antiparasitic; Protozoacide; Antianemic.

A subject who has colon cancer that expressed the CEA antigen was given a 100 mg/m2 dose of the bi-specific **antibody** hMN-14 multiply 374 F(ab')2 multiply Fab'. After 24 hours, the subject was then given an equimolar dose of the indium coupled of the AcLys (diethylenetriaminepentaacetic acid)Glu6(SN-38)6Lys(diethylenetriaminepentaacetic acid)NH2 diethylenetriaminepentaacetic acid-polymer-drug, conjugate. The diethylenetriaminepentaacetic acid-polymer-drug was localized selectively at the tumor due to the pretargeting with the multi-specific **antibody**, causing a high concentration of the active agent SN-38 to also be localized. Over time, free SN-38 was released from the localized conjugate, exerting a therapeutic effect on the tumors.

MECHANISM OF ACTION - Immunotherapy.

USE - The method is useful for diagnosing or treating a disease or disorder chosen from cancer (esophageal, gastric, colonic, rectal, pancreatic, lung, breast, ovarian, urinary bladder, endometrial, cervical, testicular, renal, adrenal and liver cancer, solid tumor, B-cell malignancy or T-cell malignancy); cardiovascular lesion; an inflammatory disease; neurodegenerative disease; metabolic disease; and an infectious disease. The B-cell malignancy is chosen from indolent forms of B-cell **lymphomas**, aggressive forms of B-cell **lymphomas**, chronic lymphatic leukemias, acute lymphatic leukemias, and **multiple myeloma**. The solid tumor is chosen melanoma, carcinoma (preferably renal carcinoma, lung carcinoma, intestinal carcinoma, and stomach carcinoma), glioma and sarcoma. The cardiovascular lesion is chosen from infarct, clot, embolus, atherosclerotic plaque and ischemia. The neurodegenerative disease is Alzheimer's disease. The metabolic disease is amyloidosis, where the **antibody** binds amyloid. The disease or disorder is displaced or ectopic normal tissue chosen from endometrium, thymus, spleen and parathyroid. The method can be used for normal tissue ablation, where the tissue is chosen from bone marrow and spleen. The disease or disorder is an autoimmune disease such as myasthenia gravis, lupus nephritis, lupus erythematosus, and rheumatoid arthritis, Class III autoimmune diseases such as immune-mediated thrombocytopenias, such as acute idiopathic thrombocytopenic purpura and chronic idiopathic thrombocytopenic purpura, dermatomyositis, Sjogren's syndrome, multiple sclerosis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous pemphigoid, diabetes mellitus, Henoch-Schonlein purpura,

post-streptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangitis ubiterans, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis, or fibrosing alveolitis. The infectious disease is chosen from bacterial, fungal, parasitic and viral lesion. The infectious disease is caused by a fungus chosen from Microsporum, Trichophyton, Epidermophyton, Sporothrix schenckii, Cyrptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, and Candida albicans. The infectious disease is caused by a virus chosen from HIV, herpes virus, cytomegalovirus, rabies virus, influenza virus, hepatitis B virus, Sendai virus, feline leukemia virus, Reo virus, polio virus, human serum parvo-like virus, simian virus 40, respiratory syncytial virus, mouse mammary tumor virus, Varicella-Zoster virus, Dengue virus, rubella virus, measles virus, adenovirus, human T-cell leukemia viruses, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocytic choriomeningitis virus, wart virus and blue tongue virus. The infectious disease is caused by a bacterium chosen from Bacillus anthracis, Streptococcus agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilus influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Mycobacterium tuberculosis, and Tetanus toxin. The infectious disease is caused by a protozoa chosen from Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiensei, Trypanosoma brucei, Schistosoma mansoni, Schistosoma japanicum, Babesia bovis, Elmeria tenella, Onchocerca volvulus, Leishmania tropica, Trichinella spiralis, Onchocerca volvulus, Theileria parva, Taenia hydatigena, Taenia ovis, Taenia saginata, Echinococcus granulosus, and Mesocestoides corti. The infectious disease is caused by a mycoplasma chosen from Mycoplasma arthritidis, M. hyorhinis, M. orale, M. arginini, Acholeplasma laidlawii, M. salivarum and M. pneumoniae. The cancer is preferably chosen from carcinoembryonic antigen (CEA)-expressing tumor or a CD20-expressing malignancy. The CD20-expressing malignancy is a B-cell **lymphoma** or leukemia (claimed).

Dwg.0/0

FILE SEGMENT: CPI EPI
FIELD AVAILABILITY: AB; DCN
MANUAL CODES: CPI: A10-E01; A12-V; A12-V01; A12-V03C2; B04-C03; B04-G01; B04-H01; B04-L05C; B05-A03A; B05-A03B; B05-A04; B05-B02A3; B05-C07; B06-A02; B06-A03; B06-F03; B07-A02B; B07-D13; B10-B01B; B10-B02A; B10-D03; B11-C07A; B12-K04A; B14-A01; B14-A02; B14-A03; B14-C06; B14-C09B; B14-F02D; B14-F03; B14-F04; B14-F07; B14-H01A; B14-H01B; B14-J01A4; B14-N10; B14-N11; B14-N12; B14-N14; B14-N15; B14-N17C; B14-S01; B14-S04; C04-C03; C04-G01; C04-H01; C04-L05C; C05-A03A; C05-A03B; C05-A04; C05-B02A3; C05-C07; C06-A02; C06-A03; C06-F03; C07-A02B; C07-D13; C10-B01B; C10-B02A; C10-D03; C11-C07A; C12-K04A; C14-A01; C14-A02; C14-A03; C14-C06; C14-C09B; C14-F02D; C14-F03; C14-F04; C14-F07; C14-H01A; C14-H01B; C14-J01A4; C14-N10; C14-N11; C14-N12; C14-N14; C14-N15; C14-N17C; C14-S01; C14-S04; D05-A01A4; D05-A01B3; D05-H09; D05-H11; K08-X; K09-B

EPI: S03-E09E; S03-E14H4

FILE 'HOME' ENTERED AT 16:22:58 ON 21 MAR 2005

=>